

Scott Richard Evans



July 24, 2018

Home:

11550 Old Georgetown Rd 416
North Bethesda, MD 20852
Tel: 774-847-9008

Office:

The Biostatistics Center
George Washington University
6110 Executive Boulevard
Suite 750
Rockville, MD 20852-3943
Tel: (301) 881-9260
FAX: (301) 881-3742
Email: sevens@bsc.gwu.edu
www.publichealth.gwu.edu/departments/epidemiology-and-biostatistics/scott-evans

Education and Training

Plymouth State College	B.S.	Mathematics	1988
University of New Hampshire	M.S.	Mathematics	1990
University of Massachusetts	Ph.D.	Biostatistics	1998

Professional Employment

Appointments

Professor, Tenured	2018-present	Department of Epidemiology and Biostatistics, George Washington University
Director	2018-present	Biostatistics Center (BSC), George Washington University
Adjunct Professor	2018	Department of Biostatistics Harvard University

Prior Appointments

Senior Research Scientist	2007-2018	Department of Biostatistics, Harvard University
Research Scientist	2002-2006	Department of Biostatistics, Harvard University
Research Associate	2000-2001	Department of Biostatistics, Harvard University

Principal Responsibilities

- Leading the scientific direction and operational administration for the BSC
- Hiring, mentoring, and evaluation of BSC faculty
- Principal Investigator for the Statistical and Data Management Centers (SDMC) for the Antibacterial Resistance Leadership Group (ARLG)
- Teaching related to clinical trials
- Mentoring of students

Leadership Roles

2018-present Chair, Executive Committee
2018-present Chair, Steering Committee
2018-present Innovations in Design, Education, and Analysis (IDEA) Committee
2018-present Funding Opportunities and Faculty Issues Committee
2018-present Website Committee

Prior Leadership Roles at Harvard University

2014-2018 Center for Biostatistics in AIDS Research (CBAR) Steering Committee
2011-2015 Co-Chair, CBAR Design Review Committee
2010-2014 CBAR Training Committee

Leadership Roles within the Clinical Research Networks

Antibacterial Resistance Leadership Group (ARLG)

2013-present Executive Committee
2013-present Steering Committee
2013-present Director, SDMC
2013-present Mentoring Committee

Neurologic AIDS Research Consortium (NARC)

2002-2012 Executive Committee
2002-2012 Director, SDMC

Oral HIV/AIDS Research Alliance (OHARA)

2006-2013 Steering Committee

AIDS Clinical Trials Group (ACTG)

2012-2013 Neurology Steering Committee and SDMC Section Head
2011-2013 End Organ Disease / Inflammation Steering Committee and SDMC Section Head
2011-2013 Coinfections and Malignancies Steering Committee and SDMC Section Head
2006-2011 OpMAN Steering Committee and SDMC Section Head
2004-2007 Co-Chair, Data Management Committee

Honors and Awards

2018 Fellow, Society for Clinical Trials
2016 Certificate of Achievement, International Chinese Statistical Association
2016 Certificate of Achievement, American Statistical Association (ASA)
Biopharmaceutical Section Regulatory-Industry Statistics Workshop
2015 Mosteller Award, Boston Chapter of the ASA
2014 Best Contributed Paper, Joint Statistical Meetings (JSM), ASA
2012 Fellow, ASA
2011 Appreciation, Committee for Advanced Scientific Education, FDA
2008 Harvard School of Public Health Recognition Award
2008 Council of Chapters Distinguished Service Award, ASA
2007 Meritorious Contributor Award, Biopharmaceutical Applied Statistics Symposium (BASS)
2006 Robert Zackin Distinguished Collaborative Statistician Award, AIDS Clinical Trials Group (ACTG)
2005 Mu Sigma Rho, the National Statistics Honorary Society, Faculty Inductee

R01 AI052817 Wei (PI) 09/30/02 – 08/31/10
NIH/NIAID
Statistical Methods for HIV/AIDS Studies
The focus of this project is to research censored regression problems that are encountered frequently in HIV/AIDS research.
Role: Investigator

U01 NS0322228 Clifford (PI) 08/01/2003 – 11/30/2011
(Subcontract from Washington University, Evans (PI))
NIH/NINDS
Neurologic AIDS Research Consortium (NARC)
The NARC conducts studies of neurological complications of HIV.
Role: Director, Statistical and Data Management Center, NARC

U01 AI068636-01 Robertson (PI) 06/01/2007 – 05/31/2013
(Subcontract from Social and Scientific Systems, Evans (PI))
NIH/NIMH
International Neurological Study
Multinational neurological and neuropsychological study in HIV.
Role: Investigator and Senior Statistician

U01 AI068636-01 Shiboski (PI) 06/01/2007 – 05/31/2013
(Subcontract from Social and Scientific Systems, Evans (PI))
NIDCR/NIH
Oral HIV/AIDS Research Alliance (OHARA)
OHARA conducts studies of oral-health complications of HIV.
Role: Investigator and Director of the Statistical and Data Analysis Center, OHARA

Publications

Articles in Refereed Journals

1. **Evans, SR**, Rubin DB, Powers JH, Follmann D. Analysis Populations in Anti-infective Clinical Trials: Whom to Analyze? *Statistical Communications in Infectious Diseases*. In press, 2018.
2. Powers J, **Evans SR**, Kesselheim AS. The Scientific Validity and Ethics of Studying New Antibiotics for Multidrug Resistant Infections: Are today's patients paying for unproven "future benefits"? *BMJ*. DOI: 10.1136/bmj.k587. 2018.
3. Huskins C, Fowler V, **Evans SR**. Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research. *CID*. 66:7:1140-1146, 2018.
4. Van Duin D, Lok J, Earley M, Cober E, Richter S, Perez F, Salata R, Kalayjian R, Watkins R, Doi Y, Kaye K, Fowler V, Paterson D, Bonomo R, **Evans SR**. Colistin vs. Ceftazidime-avibactam in the Treatment of Infections due to Carbapenem-Resistant Enterobacteriaceae, *CID*, 66:2:163-171, 2018.
5. Suissa S, Israel E, Donohue J, **Evans SR**, Kemp J. FDA-Mandated Trials of LABA Safety in Asthma: Bank for the Buck? *American Journal of Respiratory and Critical Care Medicine- Blue*. In press. 2018.
6. Wong KSL, Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Himmelmann A, Kasner S, Ladenvall P, Ladenvall P, Minematsu K, Molina CA, Wang Y, Johnston SC. Efficacy and Safety of Ticagrelor in Relation to Prior Aspirin Usage in the SOCRATES Trial. *Stroke*. DOI: 10.1161/STROKEAHA.118.020553. 2018.

7. Gewandter JS, Brell J, Cavaletti G, Dougherty PM, **Evans SR**, Howie L, McDermott MP, O'Mara A, Smith AG, Dastros-Pitei D, Gauthier LR, Haroutounian S, Jarpe M, Katz NP, Loprinzi C, Richardson P, Smith EML, Wen PY, Turk DC, Dworkin RH, Freeman R. Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTION recommendations. *Neurology*, 2018.
8. **Evans SR**, Powers J. Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls? *Statistical Communications in Infectious Diseases*. DOI: 10.1515/scid-2016-0003. 2017.
9. **Evans SR**, Hujer A, Jiang H, Hill C, Hujer K, Mediavilla J, Manca C, Tran TT, Domitrovic T, Higgins P, Seifert H, Kreiswirth BN, Patel R, Jacobs M, Chen L, Sampath R, Hall T, Marzan C, Fowler V, Chambers H, Bonomo R. Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics (RMDs) to Identify Susceptibility and Resistance to Carbapenems against *Acinetobacter* spp. PRIMERS III. *Journal of Clinical Microbiology*. 55:1:134-144, 2017.
10. Patel R, Tsalik EL, Petzold E, Fowler Jr. VG, Klausner JD, **Evans SR**. MASTERMIND – Bringing Microbial Diagnostics to the Clinic. *CID*. 2017; 64(3):355–60.
11. Huvane J, Komarow L, Hill C, Tran TT, Pereira C, Rosenkranz S, Finnemeyer M, Earley M, Jiang H, Wang R, Lok J, **Evans SR**. Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. *CID*. 64:S18-23; 2017.
12. Chambers H, Cross H, **Evans SR**, Kreiswirth B, Fowler V. The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress. *CID*. 64:S3-7; 2017.
13. Manca C, Hill C, Hujer A, Patel R, **Evans SR**, Bonomo R, Kreiswirth B. Leading Antibacterial Laboratory Research by Integrating Conventional and Innovative Approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group. *CID*. 64:S13-17; 2017.
14. Anderson, Jenkins, **Evans SR**, Harris, Weinstsein, Tamma, Han, Banerjee, Patel, Zaoutis, Lautenbach. The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group. *CID*. 64:S36-40; 2017.
15. Tsalik, Petzold, Kreiswirth, Bonomo, Banerjee, Lautenbach, **Evans SR**, Hanson, Patel. Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group. *CID*. 64:S41-47; 2017.
16. Sugimoto T, Hamasaki T, **Evans SR**, Sozu T. Sizing clinical trials when comparing bivariate time-to-event outcomes. *Statistics in Medicine*. 2017.
17. Hamasaki T, **Evans SR**, Asakura K. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: a review. *Statistics in Biopharmaceutical Research*, 2017.
18. Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong L, Johnston SC. Efficacy of Ticagrelor Versus Aspirin in Acute Stroke or Transient Ischemic Attack of Atherosclerotic Origin (SOCRATES): a Subgroup Analysis of a Randomized, Double-blind Trial. *Lancet Neurology*. 2017.
19. Gewandtera JS, McDermott MP, Kitt RA, Chaudari J, Koch JG, **Evans SR**, Gross RA, Markman JD, Turk DC, Dworkin RH. Interpretation of confidence intervals in clinical trials with non-significant results: systematic review and recommendations. *BMJ Open*. 2017.
20. Celestin A, Odom SR, Angelidou K, **Evans SR**, Cook CH. Novel Method Suggests Global Superiority of Short Duration Antibiotics for Intra-abdominal Infections. *CID*. 2017.

21. Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong L, Johnston SC. Ticagrelor versus aspirin in acute embolic stroke of undetermined source (ESUS). *Stroke*. 2017.
22. Easton JD, Aunes M, Albers GW, Amarenco P, Bokelund Singh S, Denison H, **Evans SR**, Held P, Jahreskog M, Jonasson J, Mimematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC; SOCRATES Steering Committee and Investigators. Risk for Major Bleeding in Patients Receiving Ticagrelor Compared with Aspirin After TIA or Acute Ischemic Stroke in the SOCRATES Study. *Circulation*. 2017.
23. Eilertson B, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, **Evans SR**, Fowler VG Jr, Bonomo RA, DeHovitz J, Kreiswirth B, van Duin D; Antibacterial Resistance Leadership Group. Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy. *Open Forum Infect Dis*. 2017.
24. **Evans SR**, Follmann D. Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation. *Statistics in Biopharmaceutical Research*. 2016.
25. **Evans SR**, Pennello G, Pantoja-Galicia N, Jiang H, Hujer AM, Hujer KM, Manca C, Hill C, Jacobs MR, Chen L, Patel R, Kreiswirth BN, Bonomo RA. Benefit:risk evaluation for diagnostics: a framework (BED-FRAME). *CID*. 2016; 63(6):812–7.
26. **Evans SR**, Harris A. Methods and issues in studies of CRE. *Virulence*. 2016.
27. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong L, and the SOCRATES Steering Committee and Investigators. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. *New England Journal of Medicine*. To appear. 2016.
28. Asakura K, Hamasaki T, **Evans SR**. Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints. *Biometrical Journal*. 2016.
29. Pennello G, Pantoja-Galicia N, **Evans SR**. Benefit-Risk Comparisons of Diagnostic Tests Based on Diagnostic Yield and Expected Utility. *Journal of Biopharmaceutical Statistics*. 26:6:1083-10972016.
30. Montepiedra G, Yuen CM, Rich ML, **Evans SR**. Totality of outcomes: A different paradigm in assessing interventions for treatment of tuberculosis. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*. Vol. 4, pp. 9-13, 2016.
31. Wen S, He W, **Evans SR**, Quartey G, Norton JD, Chuang-Stein C, Jiang Q, Ma H, Bhattacharya M. Practical Analysis and Visualization Tools for Benefit-Risk Assessment in Drug Development: A Review of Recent FDA Advisory Committee Meeting Packages. *Statistics in Biopharmaceutical Research*. 2016.
32. Ma H, Jiang Q, Chuang-Stein C, **Evans SR**, He W, Quartey G, Scott J, We S, Arani R. Considerations on Endpoint Selection, Weighting Determination, and Uncertainty Evaluation in the Benefit-Risk Assessment of Medical Product. *Statistics in Biopharmaceutical Research*. 2016.
33. Wang Y, Minematsu K, Wong KSL, Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Jonasson J, Molina CA, Johnston SC. Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial. *Stroke*. 2016.
34. Gewandter JS, Kitt RA, Hunsinger MR, Poku J, Lozano J, **Evans SR**, Gross RA, McDermott MP, Rowbotham MC, Turk DC, Dworkin RH. Reporting of data and safety monitoring boards (DSMB) in publications of randomized clinical trials: An ACTTION systematic review. Reporting of data and safety monitoring boards (DSMB) in publications of randomized clinical trials: An ACTTION systematic review. *Clinical Epidemiology*. 2016.
35. Robertson K, Jiang H, **Evans SR**, Marra CM, Berzins B, Hakim J, Sacktor N, Silva MT, Campbell TB, Nair A, Schouten J; With the 5271 study team, Kumwenda J,

- Supparatpinyo K, Tripathy S, Kumarasamy N, la Rosa A, Montano S, Mwafongo A, Firnhaber C, Sanne I, Naini L, Amod F, Walawander A; AIDS Clinical Trials Group. International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. *J Neurovirol.* 22:4:472-478, 2016.
36. Rojas LJ, Salim M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Marshall S, Rudin SD³, Domitrovic RN, Hujer AM, Hujer KM, Doi Y, Kaye KS, **Evans SR**, Fowler Jr VG, Bonomo RA, van Duin D. Colistin Resistance in Carbapenem-Resistant *Klebsiella pneumoniae*: Laboratory Detection and Impact on Mortality. *CID.* 2016.
 37. Hauck C, Cober E, Richter S, Perez F, Salata R, Kalayjian R, Watkins R, Scalera N, Doi Y, Kaye K, **Evans SR**, Fowler V, Bonomo R, van Duin D. Spectrum of Excess Mortality due to Carbapenem-Resistant *Klebsiella pneumoniae* Infections. *Clinical Microbiology and Infection.* 2016.
 38. Frank and the Huntington Study Group Investigators. Effect of deutetrabenazine on chorea among patients with Huntington Disease: a randomized clinical trial. *JAMA.* 2016.
 39. Mukherjee PK, Chen H, Patton L, **Evans SR**, Kumwenda J, Hakim J, Masheto G, Sawe F, Pho MT, Freedberg KA, Shiboski CH, Ghannoum MA, Salata RA. Topical gentian violet compared to nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1 Infected participants. *AIDS.* 2016.
 40. **Evans SR** and Follmann D. Fundamentals and Innovation in Antibiotic Trials. *Statistics in Biopharmaceutical Research.* 7:4, 331-336, DOI:10.1080/19466315.2015.1094406. 2015.
 41. **Evans SR**, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler Jr. VG, Lautenbach E, Chambers HF. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). *CID.* 61, 800–806. 2015.
 42. **Evans SR**, Hujer AM, Jiang H, Hujer KM, Hall T, Marzan C, Jacobs MR, Sampath R, Ecker DJ, Manca C, Chavda K, Zhang P, Fernandez H, Chen L, Mediavilla JR, Hill CB, Perez F, Caliendo A, Fowler Jr. VG, Chambers HF, Kreiswirth BN, and Bonomo RA. Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. *CID.* DOI: 10.1093/cid/civ837. 2015.
 43. Uno H, Wittes J, Fu H, Solomon SD, Claggett B, Tian L, Cai T, Pfeffer MA, **Evans SR**, Wei LJ. Alternatives to hazard ratios for comparing efficacy or safety of therapies in noninferiority studies. *Annals of Internal Medicine.* doi:10.7326/M14-1741. 2015.
 44. Ando Y, Hamasaki T, **Evans SR**, Asakura K, Sugimoto T, Sozu T, Ohno Y. Sample size considerations in clinical trials when comparing two interventions using multiple co-primary binary relative risk contrasts. *Statistics in Biopharmaceutical Research.* 2015.
 45. Hamasaki T, Asakura K, **Evans SR**, Sugimoto T, Suzo T. Group-sequential Strategies in Clinical Trials with Multiple Co-primary Outcomes. *Statistics in Biopharmaceutical Research.* 2015.
 46. Ochiai T, Hamasaki T, **Evans SR**, Asakura K, Ohno Y. Group-sequential three-arm noninferiority clinical trial designs. *Journal of Biopharmaceutical Statistics.* 2015.
 47. van Duin D, Cober E, Richter S, Perez F, Kalayjian R, Salata R, **Evans SR**, Fowler V, Kaye K, Bonomo R. Impact of Therapy and Strain Type on Outcomes in Urinary Tract Infections Caused by Carbapenem-Resistant *Klebsiella pneumoniae*. *Journal of Antimicrobial Therapy.* 2015.
 48. van Duin D, Cober E, Richter S, Perez F, Kalayjian R, Salata R, **Evans SR**, Fowler V, Bonomo R, Kaye K. Residence in Skilled Nursing Facilities is Associated with

- Tigecycline Non-Susceptibility in Carbapenem-Resistant *Klebsiella pneumoniae*. *Infection Control and Hospital Epidemiology*. 2015.
49. Messina JA, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Scalera NM, Doi Y, Kaye KS **Evans SR**, Bonomo RA, Folwer Jr VG, van Duin D. Hospital Readmissions in Patients with Carbapenem-Resistant *Klebsiella pneumoniae*. *Infection Control and Hospital Epidemiology*. 2015.
 50. Lee A, Bosch RJ, **Evans SR**, Wu K, Harrison T, Grant P, Clifford DB. Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen. *Journal of NeuroVirology*. 2015.
 51. Shiboski CH, Chen H, Secours R, Lee A, Webster-Cyriaque J, Ghannoum M, **Evans SR**, Bernard D, Reznik D, Dittmer DP, Hosey L, Sévère P, Aberg JA. High accuracy of common HIV-related oral disease diagnoses by non-oral health specialists in the AIDS Clinical Trial Group. *PLOS ONE*. 2015.
 52. Adejumo O, Oladeji B, Akpa O, Malee K, Baiyewu O, Ogunniyi A, **Evans SR**, Berzins B, Taiwo B. Psychiatric disorders and adherence to antiretroviral therapy among a population of HIV-infected adults in Nigeria. *International Journal of STD & AIDS*. 27:11: DOI:10.1177/0956462415600582. 2015.
 53. Andrews NA, Latremoliere A, Basbaum AI, Mogil JS, Porreca F, Rice ASC, Woolf CJ, Currie GL, Dworkin RH, Eisenach JC, **Evans SR**, Gewandter JS, Gover TD, Handwerker H, Huang W, Iyengar S, Jensen MP, Kennedy JD, Lee N, Levine J, Lidster K, Machin I, McDermott MP, McMahan SB, Price TJ, Ross SE, Scherrer G, Seal RP, Sena ES, Silva E, Stone L, Svensson CI, Turk DC, Whiteside G. Ensuring transparency and minimization of methodologic bias in preclinical pain research: PPRECISE recommendations. *Pain*. 2015.
 54. Asakura K, Hamasaki T, Sugimoto T, Hayashi K, **Evans SR**, Sozu T. Sample size determination in group-sequential clinical trials with two co-primary endpoints. *Statistics in Medicine*. 2014.
 55. Chambers HF, Bartlett JG, Bonomo RA, Cosgrove S, Cross H, Daum RS, **Evans SR**, Kreiswirth B, Lautenbach E, Patel R, Pettigrew MM, Rodvold K, Spellberg B, Fowler VG. Antibacterial Resistance Leadership Group: Open for Business. *CID*. 2014.
 56. Stafford KA, Boutin M, **Evans SR**, Harris AD. Difficulties in demonstrating superiority of an antibiotic for multi-drug resistant bacteria in non-randomized studies. *CID*. 2014;59(8):1142–7.
 57. van Duin D, Cober E, Richter SS, Perez F, Cline M, Kaye KS, Kalayjian RC, Salata RA, **Evans SR**, Fowler VG, Bonomo RA. Tigecycline Therapy for Carbapenem-Resistant *Klebsiella pneumoniae* (CRKP) Bacteriuria Leads to Tigecycline Resistance. *Clin Microbiol Infect*. 2014 Jun 14. doi: 10.1111/1469-0691.12714. PMID: 24931918. 2014.
 58. van Duin D, Perez F, Rudin SD, Cober E, Hanrahan J, Ziegler J, Webber R, Fox J, Mason P, Richter SS, Cline M, Hall GS, Kaye KS, Jacobs MR, Kalayjian RC, Salata RA, Segre JA, Conlan S, **Evans SR**, Fowler VG Jr, Bonomo RA. Surveillance of Carbapenem-Resistant *Klebsiella pneumoniae*: Tracking Molecular Epidemiology and Outcomes through a Regional Network. *Antimicrob Agents Chemother*. 2014 Jul;58(7):4035-4041. Epub 2014 May 5. PMID: 24798270. 2014.
 59. Shiboski, CH, Chen H, Ghannoum M, Komarow L, **Evans SR**, Mukherjee P, Isham N, Katzenstein D, Davind k, Asmelash A, Omozoarhe AE, Gengiah S, Allen R, Tripathy S, Swindells S. Role of Oral Candidiasis in Tuberculosis and HIV co-Infection: AIDS Clinical Trial Group Protocol A5253. *The International Journal of Tuberculosis and Lung Disease*. 2014.
 60. Kalayjian RC, Wu K, **Evans SR**, Clifford DB, Pallaki M, Currier JS, Smurzynski M. Proteinuria is Associated with Neurocognitive Impairment in Antiretroviral Therapy Treated HIV-infected Individuals. *JAIDS*. 2014.

61. Dorsey R. and the Huntington Study Group REACH2HD Investigators. PBT2 in Huntington disease: a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet Neurology*. 2014.
62. Sacktor N, Miyahara S, **Evans SR**, Schifitto G, Cohen B, Haughey N, Drewes JL, Graham D, Zink MC, Anderson C, Nath A, Pardo CA, McCarthy S, Hosey L, Clifford D. Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV seropositive individuals with cognitive impairment. *Journal of Neurovirology*. 2014.
63. Sugimoto T, Sozu T, Hamasaki T, **Evans SR**. A Logrank Test-Based Method for Sizing Clinical Trials with Two Co-Primary Time-to-Event Endpoints. *Biostatistics*. doi:10.1093/biostatistics/kxs057; pp. 1-13; 2013.
64. Hamasaki T, **Evans SR**. Noninferiority Clinical Trials: Issues in Design, Monitoring, Analyses, and Reporting. *Igaku no Ayumi* (Japanese) Translation: Journal of Clinical and Experimental Medicine, 244;13;1212-1216; 2013.
65. Hamasaki T, Sugimoto T, **Evans SR**, Sozu T. Sample Size Determination for Clinical Trials with Co-Primary Outcomes: Exponential Event-Times. *Pharmaceutical Statistics*. 12:28-34; 2013.
66. Harrison T, Miyahara S, Lee A, **Evans SR**, Bastow B, Simpson D, Gilron I, Dworkin R, Daar ES, Wieclaw L, Clifford DB. Experience and Challenges Presented by a Multicenter Crossover Study of Combination Analgesic Therapy for the Treatment of Painful HIV-Associated Polyneuropathies. *Pain Medicine*. doi: 10.1111/pme.12084; 2013.
67. Ghannoum MA, Mukherjee PK, Warshaw EM, **Evans SR**, Korman N, Tavakkol A. Molecular Analysis of Dermatophytes Suggests Spread of Infection among Household Members. *Cutis* 91; 2013.
68. Chen H, Clifford DB, Deng L, Wu K, Lee AJ, Bosch R, Ellis RJ, **Evans SR**. Peripheral Neuropathy in ART-Experienced Patients: Prevalence and Risk Factors. *Journal of Neurovirology*. 2013.
69. Nakasujja N, Miyahara S, Evans SR, Lee A, Musisi S, Katabira E, Robertson K, Ronald A, Clifford DB, Sacktor N. A randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. *Neurology*, 80:196-202, 2013.
70. **Evans SR**, Lee AJ, Ellis RJ, Chen H, Wu K, Bosch RJ, Clifford DB. HIV Peripheral Neuropathy Progression: Protection with Glucose-Lowering Drugs? *Journal of NeuroVirology*, DOI 10.1007/s13365-012-0119-9, 2012.
71. Robertson K, Jiang H, Kumwenda J, Supparatpinyo K, **Evans SR**, Campbell TB, et.al. Improved Neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group Study A5199, the International Neurological Study. *CID* 55(6):868-876, 2012.
72. **Evans SR**, Ellis RJ, Chen H, Yeh TM, Lee AJ, Schifitto G, Wu K, Bosch RJ, McArthur JC, Simpson DM, Clifford DB. Peripheral Neuropathy in HIV: Prevalence and Risk Factors. *AIDS*, 25:919-928, 2011. [PMCID: PMC3196556](#).
73. Sacktor N, Miyahara S, Deng L, **Evans SR**, Schifitto G, Cohen BA, Paul R, Robertson K, Jarocki B, Scarsi K, Coombs RW, Zink MC, Nath A, Smith E, Ellis RJ, Singer E, Weihe J, McCarthy S, Hosey L, Clifford DB, ACTG A5235 team. Minocycline Treatment for HIV-Associated Cognitive Impairment: Results from a Randomized Trial. *Neurology*. 2011 Sep 20;77(12):1135-42. PubMed PMID: 21900636; PubMed Central PMCID: PMC3174065.
74. Schifitto G, Deng L, Yeh TM, **Evans SR**, Ernst T, Zhong J, Clifford DB. Clinical, Laboratory, and Neuroimaging Characteristics of Fatigue in HIV-infected Individuals. *Journal of Neurovirology*, 17:17-25, 2011.

75. Robertson K, Jiang J, Kumwenda J, Supparatpinyo K, **Evans SR**, Price R. A Multinational Study of Neurological Performance in Antiretroviral Therapy-Naïve HIV-1-Infected Persons in Diverse Resource-Constrained Settings. *Journal of Neurovirology*, 2011.
76. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, **Evans SR**, Collier AC, Taylor M, Ellis R. Effects of Central Nervous System Antiretroviral Penetration on Cognitive Functioning in the ALLRT Cohort. *AIDS*, 25:3: 357-365, 2011.
77. Fichtenbaum CJ, **Evans SR**, Aberg JA. High-Sensitivity C-Reactive Protein Levels do not Decrease with the Use of Statins in All Persons with HIV Infection. *AIDS* (letter correspondence) 25:2053, 2011.
78. **Evans SR**. Fundamentals of Clinical Trial Design. *Journal of Experimental Stroke & Translational Medicine*, 3:1:19-27, 2010.
79. **Evans SR**. Clinical Trial Structures. *Journal of Experimental Stroke & Translational Medicine*, 3:1:8-18, 2010.
80. **Evans SR**. Common Statistical Concerns in Clinical Trials. *Journal of Experimental Stroke & Translational Medicine*, 3:1:1-7, 2010.
81. **Evans SR**. Estudos Clinicos de Nao-Inferioridade. *Revista Brasileira de Medicina*, 2010.
82. Yeh TM, **Evans SR**, Gulick RM, Clifford DB. Vicriviroc and Peripheral Neuropathy: Results from ACTG 5211. *HIV Clinical Trials*, 11:1:51-58, 2010.
83. Zhao Y, Navia BA, Marra CM, Singer EJ, Chang L, Berger J, Ellis RJ, Kolson DL, Simpson D, Miller EN, Lipton SA, **Evans SR**, Shiffitto G. Memantine for AIDS Dementia Complex: Open-label Report of ACTG 301. *HIV Clinical Trials*, 11:1:59-67, 2010.
84. Fichtenbaum C, Yeh T, **Evans SR**, Aberg J. Treatment with Pravastatin and Fenofibrate Improves Atherogenic Lipid Profiles but not Inflammatory Markers in ACTG 5087. *Journal of Clinical Lipidology*, 2010.
85. Glickman M, **Evans SR**. The 2009 New England Symposium on Statistics in Sports. *Journal of Quantitative Analysis in Sports*, 6:2:13, 2010.
86. Robertson K, Su Z, Margolis DM, Krambrink A, Havlir DV, **Evans SR**, Skiest DJ. Neurocognitive Effects of Treatment Interruption in Stable HIV-Positive Patients in an Observational Cohort. *Neurology*, 74:16:1260-1266, 2010.
87. **Evans SR**. Noninferiority Clinical Trials. *Chance*, 22:3:53-58, 2009.
88. Li L, **Evans SR**, Uno H, Wei LJ. Predicted Interval Plots: A Graphical Tool for Data Monitoring in Clinical Trials. *Statistics in Biopharmaceutical Research*, 1:4:348-355, 2009. PMID: 21423789; PMCID: PMC3059316
89. Clifford DB, **Evans SR**, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaldo H, Gulick RM. Long-term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals. *HIV Clinical Trials*, 10:6:343-355, 2009.
90. Clifford DB, Smurzynski M, Zhao Y, Park LS, Blair L, Arens M, **Evans SR**. The Neurological Effects of Active Hepatitis C Virus Replication on Cognition in Treated HIV Patients. *Neurology* 73:309-314, 2009. Response letter to comments 2009.
91. Tebas P, Zhang J, Hafner R, Tashima K, Shevits A, Yarasheski K, Berzins B, Owens S, Forand J, **Evans SR**, Murphy R. Peripheral and Visceral Fat Changes Following a Treatment Switch to a Nonthymidine Analog or Nucleoside-sparing Regimen in HIV-Infected Subjects with Peripheral Lipoatrophy: Results of ACTG A5110. *Journal of Antimicrobial Chemotherapy*, 63(5):998-1005; doi:10.1093/jac/dkp071, 2009.
92. Marra C, Zhao Y, Clifford D, **Evans SR**, Letendre S, Ellis R, Aweeka F, Schifitto G, Coombs R, Robertson K. Suppression of HIV Replication in Plasma Requires Suppression of HIV Replication in CSF. *AIDS*, 23:11:1359-1366, 2009.

93. Valcour V, Yeh TM, Bartt R, Clifford DB, Gerschenson M, **Evans SR**, Cohen BA, Hauer P, Millar L, Gould M, Tran P, Shikuma C, Souza S, McArthur JC. Acetyl-L-Carnitine and NRTI-associated neuropathy in HIV-infection. *HIV Medicine*, 10:2:103-110, 2009.
94. **Evans SR**. Benefit:Risk Evaluation in Clinical Trials. *Drug Information Journal*, 42:3:221, 2008.
95. **Evans SR**, Glickman. New England Symposium on Statistics in Sports. *Journal of Quantitative Analysis in Sports*, 4:2: Article 1, 2008.
96. **Evans SR**, Clifford DB, Kitch DW, Goodkin D, Schifitto G, McArthur JC, Simpson DM. Simplification of the Research Diagnosis of HIV-Associated Peripheral Neuropathy. *HIV Clinical Trials*, 9:6:434-438, 2008.
97. Robertson K, Kopinsky K, Hakim J, Merry C, Nakasujja N, Hall C, Traore M, Sacktor N, Clifford D, Newton C, Van Rie A, Holding P, Clements J, Zink C, Mielke J, Hosseinipour M, Lalloo U, Amod F, Marra C, **Evans SR**, Liner J. Second Assessment of NeuroAIDS in Africa. *Journal of NeuroVirology*, 2:22:1-13, 2008.
98. **Evans SR**, Li L, Wei LJ. Data Monitoring in Clinical Trials Using Prediction. *Drug Information Journal*, 41:733-742, 2007.
99. **Evans SR**, Fichtenbaum C, Aberg J. Comparison of Direct and Indirect Measurement of LDL in HIV Infected Individuals: ACTG 5087. *HIV Clinical Trials*, 8:1:45-52, 2007.
100. **Evans SR**. When and How Can Endpoints Be Changed after Initiation of a Randomized Clinical Trial? *Public Library of Science (PLoS) Clinical Trials* 2(4): e18. doi:10.1371/journal.pctr.0020018, 2007.
101. **Evans SR**, Simpson D, Kitch DW, King A, Clifford DB, Cohen BA, McArthur JC. A Randomized Trial Evaluating Prosaptide™ for HIV-Associated Sensory Neuropathies: Use of an Electronic Diary to Record Neuropathic Pain. *PLoS ONE*, 2(7): e551. doi:10.1371/journal.pone.0000551, 2007.
102. **Evans SR**, Yeh T, Sacktor N, Clifford DB, Simpson D, Miller EN, Ellis RJ, Valcour V, Marra CM, Millar L, Shifitto G. Selegiline Transdermal System (STS) for HIV-Associated Neurocognitive Impairment: Open-label Report of ACTG 5090. *HIV Clinical Trials*, 8:6:437-446, 2007.
103. **Evans SR**, Wang R, Haija R, Zhang J, Rajcic N, Xanthakis V, Peeples L, Anderson J, Sinha S. Evaluation of Distance Learning in an Introduction to Biostatistics Course. *Statistical Education Research Journal*, 6(2):59-77, 2007.
104. Clifford DB, Mitike MT, Mekonnen Y, Zhang J, Zenebe G, Melaku Z, Zewde A, Gessesse N, Wolday D, Messele T, Teshome M, **Evans SR**. Neurological Evaluation of Untreated HIV Infected Adults in Ethiopia. *Journal of NeuroVirology*, 13:1-6, 2007.
105. Schifitto G, Zhang J, **Evans SR**, Sacktor N, Simpson D, Millar L, Hung V, Miller E, Smith E, Ellis RJ, Valcour V, Singer E, Marra C, Kolson D, Weihe J, Rimmel R, Katzenstein D, Clifford D. A Randomized, Placebo-Controlled Study of Selegiline Transdermal System for the Treatment of HIV-Associated Cognitive Impairment. *Neurology*, 69:1314-1321, 2007.
106. Zhou L, Kitch DW, **Evans SR**, Raman S, Hauer P, Ebenezer GJ, Gerschenson M, Marra CM, Valcour V, Diaz-Arrastia R, Goodkin K, Millar L, Shriver S, Asmuth DM, Clifford DB, Simpson DM, McArthur JC. Correlates of Epidermal Nerve Fiber Densities in HIV-associated Distal Sensory Polyneuropathy. *Neurology*, 68:24:2113-2119, 2007.
107. Tebas P., Zhang J., Yarasheski K., **Evans SR**, Fischl MA, Shevitz A, Feinberg J, Collier AC, Shikuma C, Brizz B, Sattler F. Switch to a PI-Containing/NRTI-Sparing Regimen (LPVr/EFV) Increases Appendicular Fat Content and Serum Lipid Levels without Affecting Glucose Metabolism or Bone Mineral Density. The Results of a Prospective Randomized Trial. ACTG 5125s. *JAIDS*, 1;45(2):193-200, 2007.

108. Robertson K, Smurzynski M, Parsons TD, Wu K, Bosch R, Wu J, McArthur JC, Collier AC, **Evans SR**, Ellis RJ. The Prevalence and Incidence of Neurocognitive Impairment in Patients on HAART. *AIDS*, 21:14::1915-1921, 2007.
109. Simpson DM, Kitch D, **Evans SR**, McArthur J, Asmuth DM, Cohen B, Goodkin K, Gerschenson M, Shikuma C, Weihe J, So Y, Marra C, Diaz-Arrastia, R, Millar L, Shriver S, Clifford DB. HIV Neuropathy Natural History Cohort Study: Assessment Measures and Risk Factors. *Neurology*, 66:1679-1687, 2006.
110. **Evans SR**, Li L. A Comparison of Goodness of Fit Tests for the Logistic GEE Model. *Statistics in Medicine*, 24:1245-1261, 2005.
111. Clifford DB, **Evans SR**, Yang Y, Gulick RM. The Neuropsychological and Neurologic Impact of HCV Co-Infection in HIV-Infected Subjects. *AIDS*, 19 (suppl 3):S64-S71, 2005.
112. Clifford DB, **Evans SR**, Yang Y, Acosta E, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaud H, Gulick RM. Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals. *Annals of Internal Medicine*, 143:714-721, 2005.
113. Ellis R, **Evans SR**, Clifford D, Moo L, McArthur J, Collier A, Benson C, Bosch R, Simpson D, Yiannoutsos C, Yang Y, Robertson K. Clinical Validation of the Neuroscreen. *Journal of NeuroVirology*, 11:6:503-511, 2005.
114. Clifford D, Yang Y, **Evans SR**. Neurologic Consequences of Hepatitis C and Human Immunodeficiency Virus Co-Infection. *Journal of NeuroVirology*, 11 (suppl 3):67-71, 2005.
115. Lopate G, Pestronk A, **Evans SR**, Li L, Clifford D. Anti-Sulfatide Antibodies in HIV-Infected Individuals with Distal Symmetric Sensory Polyneuropathy. *Neurology*, 64:1632-1634, 2005.
116. Aberg JA, Zackin RA, Brobst SW, **Evans SR**, Alston BL, Henry WK, Glesby MJ, Torriani FJ, Yang Y, Owens SI, Fichtenbaum CJ. A Randomized Trial of the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects with Lipid Abnormalities: AIDS Clinical Trials Group Study 5087. *AIDS Research and Human Retroviruses*, 21:9:757-767, 2005.
117. D'Amico R, Yang Y, Mildvan D, **Evans SR**, Schnizlein-Bick CT, Hafner R, Webb N, Basar M, Zackin R, Jacobson MA. Lower CD4+ T Lymphocyte Nadirs May Indicate Limited Immune Reconstitution in HIV-1 Infected Individuals on Potent Antiretroviral Therapy: Analysis of Immunophenotypic Marker Results of ACTG 5067. *Journal of Clinical Immunology*, 25:2:106-115, 2005.
118. Osman MA, **Evans SR**. Time Series Analysis of the Somalian Export Demand Equations: A Cointegration Approach. *Journal of Economic and Social Research*, 4:2:71-92, 2005.
119. **Evans SR**, Hosmer DW. Goodness of Fit Tests for Mixed Effects Logistic Models. *Communications in Statistics: Theory and Methods*, 33:5:1139-1155, 2004.
120. **Evans SR**, Hosmer DW. Goodness of Fit Tests for Logistic GEE Models: Simulation Results. *Communications in Statistics: Simulation and Computation*, 33:1:247-258, 2004.
121. Wohl DA, Pilcher CD, **Evans SR**, Revuelta M, McComsey G, Yang Y, Zackin R, Alston B, Welch S, Basar M, Kashuba A, Kondo P, Martinez A, Giardini J, Quinn J, Littles M, Wingfield H, Koletar SL. Absence of Sustained Hyperlactatemia Among HIV-Infected Patients with Risk Factors for Mitochondrial Toxicity. *Journal of Acquired Immune Deficiency Syndromes (JAIDS)*, 35:3:274-278, 2004.
122. Simpson D, Estanislao L, **Evans SR**, McArthur J, Marcus K, Truufa M, Lucey B, Naismith R, Lonergan T, Clifford D. HIV-Associated Neuromuscular Weakness Syndrome. *AIDS*, 18:10:1403-1412, 2004.

123. Shikuma CM, Zackin R, Sattler F, Mildvan D, Nyangweso P, Alston B, **Evans SR**, Mulligan K. Changes in Weight and Lean Body Mass during Highly Active Anti-Retroviral Therapy. *Clinical Infectious Diseases*, 39:1223-1230, 2004.
124. **Evans SR**, Testa MA, Cooley TP, Krown SE, Paredes J, Von Roenn JH. A Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma: An ACTG Clinical Study. *Journal of Clinical Oncology*, 20:15:3236-3241, 2002.
125. Swindells S, **Evans SR**, Zackin R, Goldman M, Haubrich R, Filler SG, Balfour Jr, HH. Predictive Value of HIV-1 Viral Load on Risk for Opportunistic Infection. *JAIDS*, 30:154-158, 2002.
126. Chung RT, **Evans SR**, Yang Y, Dickens T, Valdez H, Clark R, Shikuma C, Nevin T, Sherman K. Immune Recovery is Associated with Persistent Rise in HCV RNA, Infrequent Liver Test Flares, and is Not Impaired by HCV in Coinfected Subjects. *AIDS*, 16:1915-1923, 2002.
127. Buonaccorsi JP, Elkinton JS, **Evans SR**, Liebhold AM. Measuring and Testing for Spatial Synchrony. *Ecology*, 82(6), pp. 1668-1679, 2001.

Articles in Non-Refereed Journals

1. Hamasaki T, Asakura K, **Evans SR**, Sugimoto T. Sample Size Modification in Group Sequential Clinical Trials with Co-Primary Endpoints. *Proceedings of the 2013 IASC Satellite for the ISI WSC and the 8th IASC-ARS Conference*. 2013.
2. **Evans SR**, Li L, Wei L. Data Monitoring in Clinical Trials Using Prediction for Data Monitoring of Clinical Trials. *ASA Proceedings of the JSM*, 2007.
3. Osman MA, **Evans SR**. International Demand of Somalia's Livestock Exports: An Error Correction Approach. *Proceedings of Theory and Policy in the Information Age*, 2005.
4. **Evans SR**, Li L. Evaluation of Goodness of Fit Tests for the Logistic GEE Model. *ASA Proceedings of the JSM*, 330-337, 2004.

Chapters in Books

1. Levitan B, DiSantostefano R, **Evans SR**. Benefit-Risk Assessments of Medical Treatments. *Pharmacoepidemiology*, Sixth Edition. Edited by Strom BL, Kimmel SE, and Hennessy S. To appear.
2. **Evans SR**, Barry W. Interim Analysis and Data Monitoring. *Oncology Clinical Trials*. 2017.
3. Moyses RA, Angelim V, **Evans SR**. Noninferiority Designs. *PPCR*. 2017.
4. Jiang Q, Ma H, Chuang-Stein C, **Evans SR**, He W, Quartey G, Scott J, Wen S, Arani R. Understanding and Evaluating Uncertainties in the Assessment of Benefit-Risk in Pharmaceutical Drug Development. *Benefit-Risk Assessment Methods in Medicinal Product Development: Bridging Qualitative and Quantitative Assessments*. CRC Press Taylor & Francis Group. 2016.
5. Wen S, He W, **Evans SR**, Ma H, Chuang-Stein C, Jiang Q, Li X, Quartey G, Arani R. Visualization of Benefit-Risk Assessment in Medicinal Products with Real Examples. *Benefit-Risk Assessment Methods in Medicinal Product Development: Bridging Qualitative and Quantitative Assessments*. CRC Press Taylor & Francis Group. 2016.
6. He W, Bloomfield D, Mai Y, **Evans SR**. Practical Considerations for Benefit Risk Assessment and Implementation: Vorapaxar TRA-2P TIMI 50 Case Study. *Benefit-Risk Assessment Methods in Medicinal Product Development: Bridging Qualitative and Quantitative Assessments*. CRC Press Taylor & Francis Group. 2016.

7. Asakura K, Hamasaki T, **Evans SR**, Sugimoto T, Sozu T. Group-sequential designs when considering two binary outcomes as co-primary endpoints. *Applied Statistics in Biomedicine and Clinical Trial Designs*, Chen Z et al (eds.), Springer 2014.

Books

1. **Evans SR** and Ting, N. *Fundamental Concepts for New Clinical Trialists*. ISBN 9781420090871 - CAT# C9087. Chapman & Hall/CRC Biostatistics Series. 2015.
2. Sozu T, Hamasaki T, Sugimoto T, **Evans SR**. *Sample size determination in clinical trials with multiple endpoints*. ISBN 978-3-319-22005-5. Springer. 2015.
3. Hamasaki T, Asakura K, **Evans SR**, Ochiai T. *Group-Sequential Clinical Trials with Multiple Co-Objectives*. •ISBN 978-4-431-55898-9. Springer. 2016.

Letters: Editors Letter

1. **Evans SR**. Editors Letter. *CHANCE* 31:4:2018.
2. **Evans SR**. Editors Letter. *CHANCE* 31:3:2018.
3. **Evans SR**. Editors Letter. *CHANCE* 31:2:2018.
4. **Evans SR**. Editors Letter. *CHANCE* 31:1:2018.
5. **Evans SR**. Editors Letter. *CHANCE* 30:4:2017.
6. **Evans SR**. Editors Letter. *CHANCE* 30:3:2017.
7. **Evans SR**. Editors Letter. *CHANCE* 30:2:2017.
8. **Evans SR**. Editors Letter. *CHANCE* 30:1:2017.
9. **Evans SR**. Editors Letter. *CHANCE* 29:4:2016.
10. **Evans SR**. Brief bits of humor in statistics: a statistician is ... *CHANCE* 29:4:61. 2016.
11. **Evans SR**. Editors Letter. *CHANCE* 29:3:2016.
12. **Evans SR**. Editors Letter. *CHANCE* 29:2:2016.
13. **Evans SR**. Editors Letter. *CHANCE* 29:1:2016.
14. Evans, SR, Kreiswirth B, Fowler V, Chambers H, Patel R, Hujer AM, Perez R, Bonomo RA. Reply to Lesho and Clifford: "In the eye of a storm": the goal of rapid molecular diagnostics in PRIMERS I and II. *CID*. 2016.
15. **Evans SR**, Follmann D, Schoenfeld D, Chambers HF. Response to Phillips et.al. *CID*. 2015.
16. **Evans SR**. Editors Letter. *CHANCE* 28:4:2015.
17. **Evans SR**. Editors Letter. *CHANCE* 28:3:2015.
18. **Evans SR**. Editors Letter. *CHANCE* 28:2:2015.
19. **Evans SR**. Editors Letter. *CHANCE* 28:1:2015.
20. **Evans SR**. Editors Letter. *CHANCE* 27:4:2014.
21. **Evans SR**. Editors Letter. *CHANCE* 27:3:2014.
22. **Evans SR**. Editors Letter. *CHANCE* 27:2:2014.
23. **Evans SR**. Editors Letter. *CHANCE* 27:1:2014.

Letters: Newsletters

1. **Evans SR**. *CHANCE Highlights: Special issue looks at statistics in defense and national security*. *AmSTAT News*, page 8. May, 2018.
2. **Evans SR**. *CHANCE Highlights: Special issue focuses on climate change*. *AmSTAT News*, January, 2018.
3. **Evans SR**. *The 2017 New England Symposium on Statistics in Sports (NESSIS) Features Retrospective Modeling, Shot Taxonomy, Randomness*. *AmSTAT News*. December 2017.
4. **Evans SR**, *The SCT Trial of the Year*. *Society for Clinical Trials Newsletter*, 2017.
5. **Evans SR**, Glickman M. *The 2017 New England Symposium on Statistics in Sports*, *Newsletter of the Boston Chapter of the American Statistical Association*, 2017.

6. **Evans SR**, Glickman M. The 2015 New England Symposium on Statistics in Sports, *Newsletter of the Boston Chapter of the American Statistical Association*, 2015.
7. **Evans SR**. The New England Statistics Symposium Sets Record Attendance. *AmSTAT News*. December 2015.
8. Cook S, **Evans SR**, Goldman R, Li M, McKenzie J, Williams K. Attractions in Boston and Cambridge. *AmSTAT News*. Issue #443, pp. 26-27. May 2014.
9. **Evans SR**. The New England Statistics Symposium a Success. *Newsletter of the Boston Chapter of the American Statistical Association*. 2014.
10. **Evans SR**, Glickman M. New England Symposium on Statistics in Sports Bridges Gaps, *AmSTAT News*, page 15, January 2013.
11. **Evans SR**, Glickman M. The 2013 New England Symposium on Statistics in Sports, *Newsletter of the Boston Chapter of the American Statistical Association*, 2013.
12. **Evans SR**. Annual Fund Drive Reaches Still Higher. *AmSTAT News*, February, p. 10-15, 2012.
13. **Evans SR**, Glickman M. Statistics in Sports Symposium Draws Enthusiasm, *AmSTAT News*, page 15, January 2012.
14. O'Brien L, Horton N, **Evans SR**. An introduction to Mu Sigma Rho for American Statistical Association Chapters. *Chapter Chatter (ASA)* 2:2:10-12. 2012.
15. **Evans SR**. Annual Fund Drive Reaches New Heights. *AmSTAT News*, February, p. 6-11, 2011.
16. **Evans SR**, Glickman M. The 2011 New England Symposium on Statistics in Sports, *Newsletter of the Boston Chapter of the American Statistical Association*, 2011.
17. **Evans SR**. The ASA Annual Fund Drive. *AmSTAT News*, February, p. 6-11, 2010.
18. Hamasaki T, **Evans SR**, Molenburgh G. Biostatistics on the Rise in Japan. *AmSTAT News*, November, 2009.
19. Oster R, Lapidus J, **Evans SR**. New Award Winners and JSM 2008 Program. *AmSTAT News*, July, 2008.
20. **Evans SR**. Chair's Report, *Newsletter of the Teaching Statistics in the Health Sciences Section of the American Statistical Association*, spring, 2008.
21. **Evans SR**. Chair's Report, *Newsletter of the Teaching Statistics in the Health Sciences Section of the American Statistical Association*, summer, 2008.
22. **Evans SR**. Chair's Report, *Newsletter of the Teaching Statistics in the Health Sciences Section of the American Statistical Association*, fall, 2008.
23. **Evans SR**. President's Report, *Newsletter of the Boston Chapter of the American Statistical Association*, 2006.
24. **Evans SR**. Changing Endpoints after a Clinical Trial Begins, *TMT Medical News*, http://masterdocs.com/PDF/Changing_Endpoints_After_A_Clinical_Trial_Begins_By_Scott_Evans.pdf, 2006.
25. **Evans SR**. Distance Education and Teaching Statistics in the Health Sciences. *Newsletter of the Teaching Statistics in the Health Sciences Section of the American Statistical Association*, fall, 2005.
26. **Evans SR**. President's Report, *Newsletter of the Boston Chapter of the American Statistical Association*, 2005.
27. Horton N, **Evans SR**. An Introduction to Mu Sigma Rho (or a Simple Guide to Honoring Outstanding Students of Statistics in Your Midst). *AmStat News*, Issue number 341, page 50, November, 2005.
28. Bernson M, **Evans SR**. Tutorials in Medicine: An Introduction to Clinical Trials; Part I of II: Purposes and Phases. <http://www.nextgenmd.org/vol1-4/clinicaltrials1i4.html>, *The Next Generation*, 2005.

29. Bernson M, **Evans SR**. Tutorials in Medicine: An Introduction to Clinical Trials; Part II of II: Statistics and Experimental Design. <http://www.nextgenmd.org/vol1-5/clinicaltrials/v1i5.html>, *The Next Generation*, 2005.
30. **Evans SR**. President's Report, *Newsletter of the Boston Chapter of the American Statistical Association*, 2004.
31. **Evans SR**. President's Report, *Newsletter of the Boston Chapter of the American Statistical Association*, 2003.
32. **Evans SR**, Kleinman K, Pagano M. Statistics in Defense and National Security: Bioterrorism and Biosurveillance. *AMSTAT News*, pp. 41-43, July, 2002.

Published Interviews and Press Releases: Interviewee

1. Internationally Recognized Leader in Clinical Trials, Biostatistics, and Infectious Disease Research Joins the George Washington University. <https://publichealth.gwu.edu/content/internationally-recognized-leader-clinical-trials-biostatistics-and-infectious-disease>. 2018.
2. Cytel and Scott Evans. How can Novel Statistical Methods Tackle Antibiotic Resistance? Interview with Scott Evans. Cytel Blog. <http://www.cytel.com/blog/novel-statistics-antibiotic-resistance-scott-evans>. 2017.
3. Evans SR. Q&A with Scott Evans, CAHNCE Executive Editor. American Statistical Association. <http://www.amstat.org/ASA/Publications/Q-and-As/Scott-Evans.aspx>.
4. Outsmarting Superbugs. Plymouth Magazine. <https://www.plymouth.edu/magazine/alumni-green/outsmarting-superbugs/>. 2016.
5. Superbugs: An Epidemic Begins. Harvard Magazine. <http://harvardmagazine.com/2014/05/superbug>. 2014.

Published Interviews: Interviewer

1. Wei LJ, Evans SR. A Conversation with LJ Wei. ICSA Newsletter. 2017.
2. Molenberghs G, Hamasaki T, Evans SR. An Interview with Geert Molenberghs. *CHANCE* 30:1:16-23, 2017.
3. Mehta C, Patel N, Evans SR. Creators of Pioneering Software Development Company Look Back and to the Future. *CHANCE* 29:3:51-57, 2016.
4. Evans SR, Kovalchik S, Lock D. Want a Career in Sports Analytics? Webinar. American Statistical Association, 2016.
5. O'Neill R. and Evans, SR. A Conversation with Bob O'Neill. Podcast available at: <http://community.amstat.org/biop/podcast>. Boston Chapter of the ASA, 2014.
6. Wittes J. and Evans SR. An Interview with Janet Wittes, President of Statistics Collaborative. *CHANCE* 27:4:15-22, 2014.

Abstracts (Last Three Years)

1. **Evans SR**, Knutsson M, Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Jonasson J, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KSL. Benefit:risk Assessment Using Novel Methodologies: Ticagrelor vs. Aspirin in Acute Stroke or Transient Ischemic Attack in the SOCRATES Trial. European Stroke Organization Conference. Gothenburg, Sweden. 2018.
2. Wilson B, Viau R, Perez F, Jiang Y, Fowler VG Jr, Chambers HF, Bonomo BA, **Evans SR**. Using the Desirability of Outcome Ranking for Management of Antimicrobial Therapy (DOOR-MAT) to assess antibiotic therapy guided by rapid molecular diagnostics (RMD) in bloodstream infections (BSI) caused by *Escherichia coli* (*Ec*) and *Klebsiella pneumoniae* (*Kpn*). *IDWEEK*. 2018.
3. Hamasaki T, **Evans SR**, Sugimoto T, Asakura K. Statistical Monitoring of Semi-competing Risk Outcomes in Clinical Trials. *JSM*. 2018.

4. Hamasaki T, **Evans SR**, Halabi S, Sugimoto T, Asakura K. Group Sequential Strategies in Clinical Trials with Bivariate Time-to-Event Outcomes. ENAR. 2018.
5. Hamasaki T, Asakura K, **Evans SR**, Halabi S, Sugimoto T. Designing Efficient Clinical Trials with Multiple Time-to-event Outcomes. IMS-APRM. Singapore. 2018.
6. Hamasaki T, **Evans SR**, Halabi S, Sugimoto T, Asakura K. Group Sequential Logrank-Based Methods for Monitoring Bivariate Non-Competing Event-Time Outcomes in Clinical Trials. DIA/FDA Statistics Forum. 2018.
7. Hamasaki T, **Evans SR**, Sugimoto T, Asakura K. Designing Complex Survival Clinical Trials with Multi-stage and Multiple Endpoints. International Biometric Conference. 2018.
8. Asakura K, Hamasaki T, **Evans SR**. Interim monitoring for futility of clinical trials with co-primary endpoints. ASA Biopharmaceutical Section Statistics Workshop. 2018.
9. Viau R, Wilson B, **Evans SR**, Perez F, Fowler Jr. VG, Chambers HF, Kreiswirth BN, Banerjee R, Patel R, Bonomo RA. Do healthcare providers de-escalate Beta-lactam (BL) antibiotic therapy based on results of antibiotic susceptibility testing (AST)? Analysis of bloodstream infections (BSI) caused by *Escherichia coli* (*Ec*) and *Klebsiella pneumoniae* (*Kpn*) from the Veterans Health Administration (VHA). IDWEEK. 2018.
10. Viau R, Wilson B, **Evans SR**, Perez F, Fowler Jr. VG, Chambers HF, Kreiswirth BN, Bonomo RA. How do healthcare providers approach empiric beta-lactam (BL) treatment of bloodstream infections (BSI) caused by Gram negative rods (GNRs)? Analysis of *Escherichia coli* (*Ec*) and *Klebsiella pneumoniae* (*Kpn*) BSI from the Veterans Health Administration (VHA). IDWEEK. 2018.
11. Johnston SC, Amarenco P, Denison H, **Evans SR**, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina C, Wang Y. The THALES (Acute STroke or Transient Ischaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death) Trial Design. European Stroke Organization Conference. Gothenburg, Sweden. 2018.
12. Hamasaki T, Asakura K, **Evans SR**, Sugimoto T, Yamamoto H. Interim Evaluation of Futility Group-sequential Trials with Two Time-to-event Outcomes. Society for Clinical Trials. 2018.
13. Easton JD, Denison H, Knutsson M, Amarenco P, Albers GW, **Evans SR**, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC. Estimated Treatment Effect of Ticagrelor vs. Aspirin by Investigator Assessed Events Compared with Judgement by an Independent Event Adjudication Committee in the SOCRATES Trial. European Stroke Organization Conference. Gothenburg, Sweden. 2018.
14. Doernberg S, Holland T, Paul M, Yahav D, Tran T, **Evans SR**, Cosgrove S, Boucher HW, Corey GR, Fowler VG, Chambers H, Leibovici L. Desirability of Outcome Ranking (DOOR) analysis of patients with methicillin-resistant *Staphylococcus aureus* bloodstream infections (BSIs) from a trial comparing trimethoprim-sulfamethoxazole (TMP-SMX) versus vancomycin. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 2018.
15. **Evans SR**. Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes. SCT. Liverpool, England. 2017.
16. **Evans SR**, Tran T, Hujer A, Manca C, Hill C, Hujer KM, Perez F, Chambers H, Fowler V, Kreiswirth BN, Patel R, Jacobs M, Bonomo RA. Promise and Peril: Rapid Molecular Diagnostics (RMDs) and Clinical Decision-Making in Infectious Diseases. ECCMID. 2017.
17. Van Duin D. and the CRACKLE Research Team. Ceftazidime/avibactam Susceptibility Patterns in Carbapenem-Resistant Enterobacteriaceae in the US: Results from the Consortium on Resistance against Carbapenems in Klebsiella and Other Enterobacteriaceae (CRACKLE-2). IDWEEK. San Diego, CA. October 2017.

18. Holland T, Davis JS, Doernberg SB, Tran TTT, **Evans SR**, Cosgrove SE, Boucher HW, Corey GR, Fowler VG, Chambers HF, Tong SYC. Analysis of CAMER *S. aureus* Bacteremia Trial Results Using the DOOR and Partial Credit Approaches. IDWEEK San Diego, CA. October 2017.
19. Asakura K, Hamasaki T, **Evans SR**. Interim monitoring of clinical trials with co-primary endpoints. Southern Statistical Conference. National Taipei University, Taiwan. 2017.
20. Asakura K, Hamasaki T, **Evans SR**. Interim evaluation of futility in clinical trials with co-primary endpoints. Joint Conference on Biometrics & Biopharmaceutical Statistics. Vienna Austria. 2017.
21. Hamasaki T, **Evans SR**, Sugimoto T, Asakura K. Designing multi-stage clinical trials with multiple event-time endpoints. JSM. Baltimore, MD USA. 2017.
22. Hamasaki T, **Evans SR**, Sugimoto T, Asakura K. Statistical monitoring of clinical trials with semi-competing risks outcomes. ENAR. Washington DC. 2017.
23. Hamasaki T, Asakura K, **Evans SR**, Yamamoto H. Efficient group-sequential designs for monitoring two time-to-event outcomes in clinical trials. SCT. Liverpool, England. 2017.
24. Asakura K, Hamasaki T, **Evans SR**, Hsiao C, Fukuda M, Yamamoto H. Interim monitoring of clinical trials with co-primary endpoints using predicted intervals. SCT. Liverpool, England. 2017.
25. Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong L, Johnston SC. Ticagrelor Versus Aspirin in Acute Stroke or Transient Ischemic Attack of Atherosclerotic Origin. International Stroke Conference, Houston, TX USA. 2017.
26. Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong L, Johnston SC. Ticagrelor Versus Aspirin in Acute Stroke or Transient Ischemic Attack of atherosclerotic Origin. European Stroke Conference, Berlin Germany. 2017.
27. Van Duin D, Arias C, Weston G, Ostrowsky B, Cober E, Richter SS, Doi Y, Garcia-Diaz J, Jacob JT, Humphries R, Kaye KS, Satlin M, Fries B, Salata R, Anderson D, Kalayjian R, Han J, Desai S, Huskins WC, Wortmann G, Farrell J, Wong D, Komarow L, Earley M, **Evans SR**, Bonomo R. National variability in patients with carbapenem-resistant Enterobacteriaceae in the US; First results from the Consortium on resistance against carbapenems in Klebsiella and other Enterobacteriaceae-II. ASM Microbe. New Orleans, LA USA. 2017.
28. Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong L, Johnston SC. Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. European Stroke Organisation Conference, Prague, Czechoslovakia. 2017.
29. Boshe A, Cober E, Perez F, Salata R, Kalayjian R, Richter S, Watkins R, Doi Y, Kaye KS, **Evans SR**, Fowler V, Bonomo R, van Duin D. Role of Trimethoprim/Sulfamethoxazole in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. ASM Microbe. New Orleans, LA USA. 2017.
30. Wong KSL, Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Jonasson J, Kasner S, Ladenvall P, Minematsu K, Molina CA, Wang Y, Johnston SC. Efficacy and Safety of Ticagrelor in Relation to Prior Aspirin Usage in the SOCRATES Trial. International Stroke Conference, Houston, TX USA. 2017.
31. Molina CA, Johnson SC, Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Jonasson J, Ladenvall P, Minematsu K, Rother J Wang Y, Wong KSL. Efficacy and Safety of Ticagrelor in Relation to Time-to-Loading Dose in the SOCRATES Trial. International Stroke Conference, Houston, TX USA. 2017.
32. **Evans SR**, Holland T, Doernberg S, Gouskova NA, Jiang J, Patillo S, Corey R, Boucher H, Fowler Jr. VG, Cosgrove SE, Chambers HF. Using endpoints to analyze patients

- rather than patients to analyze endpoints: A pre-trial substudy to develop a global outcome for clinical trials. SCT. Montreal, Canada, 2016.
33. **Evans SR**, Tran TT, Hujer A, Hill C, Hujer KM, Mediavilla JR, Manca C, Domitrovic TN, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler V, Chambers H, Bonomo R. Choosing Ceftazidime/Avibactam and Ceftolozane/Tazobactam as Empiric Therapies against *Pseudomonas aeruginosa* (Pa) using Rapid Molecular Diagnostics (RMDs): PRIMERS IV. ID WEEK. New Orleans, LA. 2016.
 34. Tran T, Holland T, Doernberg S, Jiang J, Patillo S, Corey R, Boucher H, Fowler Jr. VG, Cosgrove SE, Chambers HF, **Evans SR**. Using endpoints to analyze patients rather than patients to analyze endpoints: A pre-trial substudy to develop a global outcome for clinical trials. JSM. Chicago, IL, 2016.
 35. Pennello G, Pantoja-Galicia N, **Evans SR**. Recent Developments in Benefit:Risk Evaluation for Diagnostic Tests. JSM. Chicago, IL, 2016.
 36. Hamasaki T, Sugimoto T, Asakura K, **Evans SR**. Group-Sequential Clinical Trials for Comparing Two Interventions Using Two Time-to-Event Outcomes. JSM. Chicago, IL, 2016.
 37. Asakura K, **Evans SR**, Hamasaki T, Sugimoto T. Early evaluation of efficacy in group-sequential clinical trials with two time-to-event endpoints. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. Washington DC, 2016.
 38. Asakura K, Hamasaki T, **Evans SR**, Fukuda M, Yamamoto H. Interim monitoring of clinical trials with co-primary endpoints using predicted intervals. SCT. Montreal, Canada, 2016.
 39. Hamasaki T, Ochiai T, **Evans SR**, Asakura K, Fukuda M, Yamamoto H. Group-Sequential Three-arm Noninferiority Designs. SCT. Montreal, Canada, 2016.
 40. Hamasaki T, Sugimoto T, Asakura K, **Evans SR**. Early Evaluation of Efficacy in Group-Sequential Clinical Trials with Two Time-to-Event Outcomes. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. Washington, DC. 2016.
 41. Doernberg S, Gouskova N, **Evans SR**, Boucher H, Corey GR, Cosgrove SE, Chambers H, Fowler Jr VG, Holland TL. BAC DOOR: A Clinician Ranking Exercise for Better *S. aureus* Bacteremia Trial Design. ID WEEK. New Orleans, LA USA. 2016.
 42. Easton JD, Albers GW, Aunes M, Amarenco P, Denison H, **Evans SR**, Held P, Jahreskog M, Johnston SC, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KSL. The Risk for Major Bleeding was Similar in Patients Receiving Ticagrelor or Aspirin after TIA or Acute Ischemic Stroke in the SOCRATES Study. AHA. New Orleans, LA. 2016.
 43. Johnston SC, Amarenco P, Albers G, Denison H, Easton JD, **Evans SR**, Held P, Jonasson J, Minematsu K, Molina C, Wang Y, Wong L. Ticagrelor vs. Aspirin in Acute Stroke or Transient Ischemic Attack: Primary Results of the SOCRATES Randomized Trial. ESOC. Barcelona, Spain, 2016.
 44. Minematsu K, Wong KSL, Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Jonasson J, Molina CA. Ticagrelor vs. Aspirin in Acute Stroke or TIA in Asian Patients: substudy from the SOCRATES Trial. Chinese Stroke Association and the Tiantan International Stroke Conference. Beijing, China. 2016.
 45. Rojas LJ, Cober E, Richter SS, Perez F, Salata R, Kalayjian R, Watkins RR, Scalera N, Doi Y, Kaye K, **Evans SR**, Fowler Jr VG, van Duin D, Bonomo R. Molecular analysis of colistin resistance among *Klebsiella pneumoniae* producing KPC (Kp-KPC): heterogeneity of genetic mechanisms. ID WEEK. New Orleans, LA USA. 2016.
 46. Van Duin D, Cober E, Richter SS, Perez F, Salata R, Kalayjian R, Watkins RR, Scalera N, Doi Y, Kaye K, **Evans SR**, Fowler Jr VG, Bonomo R. Colistin versus

- Ceftazidime/Avibactam in the Treatment of Carbapenem-Resistant *Klebsiella pneumoniae* Infections. ECCMID. Amsterdam, Netherlands, 2016.
47. **Evans SR**, Jiang H, Hujer AM, Hujer KM, Mediavilla J, Manca C, Hill C, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall R, Marzan C, Fowler Jr VG, Chambers H, Bonomo RA. Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics (RMDs) to Identify Susceptibility and Resistance to Carbapenems against *Acinetobacter* spp. PRIMERS –III. ID WEEK. San Diego, CA. 2015.
 48. **Evans SR**, Jiang H, Hujer AM, Hujer KM, Manca C, Hill C, Kreiswirth BN, Jacobs MR, Chen L, Sampath R, Hall R, Marzan C, Bonomo RA. Benefit:Risk Evaluation in Diagnostics: An Example Comparing Two Rapid Molecular Diagnostics Testing Imipemem Susceptibility in *Acinetobacter* spp. ID WEEK. San Diego, CA. 2015.
 49. Van Duin D, Perez F, Cober E, Richter SS, Kalayjian R, Salata R, Scalera N, Watkins RR, Doi Y, **Evans SR**, Fowler Jr VG, Kaye K, Rudin SD, Hujer KM, Hujer AM, Bonomo R, Moody J. The Movement of Carbapenem-Resistant *Klebsiella pneumoniae* among Healthcare Facilities: A Network Analysis. ID WEEK. San Diego, CA. 2015.
 50. Salim M, Perez F, Cober E, Richter SS, Kalayjian R, Salata R, Scalera N, Watkins RR, Doi Y, **Evans SR**, Fowler Jr. VG, Bonomo R, Kaye K, Van Duin D. Colistin Resistance in Patients with Carbapenem-resistant *Klebsiella pneumoniae* is Associated with Increased Mortality. ID WEEK. San Diego, CA. 2015.
 51. He W, Wen S, **Evans SR**. Graphical presentation of benefit-risk profile. JSM Seattle, WA 2015.
 52. Hamasaki T, Asakura K, **Evans SR**. Group-sequential strategies for clinical trials when comparing two interventions using multiple co-primary endpoints. JSM Seattle, WA 2015.
 53. Sugimoto T, Hamasaki T, **Evans SR**, Sozu T. Sizing clinical trials when comparing two interventions using two time-to-event outcomes. JSM Seattle, WA 2015.
 54. Asakura K, Hamasaki T, **Evans SR**. Early stopping for futility or efficacy in group-sequential clinical trials with multiple co-primary endpoints. JSM Seattle, WA 2015.
 55. Asakura K, Hamasaki T, **Evans SR**, Fukuda M, Yamamoto H. Group-sequential strategies for clinical trials with co-primary endpoints. Society for Clinical Trials. Crystal City, VA. 2015.
 56. Hamasaki T, Sugimoto T, Asakura K, **Evans SR**, Fukuda M, Yamamoto H. Sample size considerations for clinical trials with two primary time-to-event outcomes. Society for Clinical Trials. Crystal City, VA. 2015.
 57. Hamasaki T, **Evans SR**, Asakura K. Group-sequential strategies for clinical trials when comparing two interventions using multiple co-primary endpoints. The ISBS/DIA Joint Symposium, Beijing, China. 2015.
 58. Hamasaki T, Asakura K, **Evans SR**. Early stopping for futility or efficacy in group-sequential clinical trials with multiple co-primary endpoints. The ISBS/DIA Joint Symposium, Beijing, China. 2015.
 59. Hamasaki T, Asakura K, **Evans SR**. Early stopping for futility or efficacy in group-sequential clinical trials with multiple co-primary endpoints. The 9th International Conference on Multiple Comparison Procedure. Hyderabad, India. 2015.
 60. Hamasaki T, Asakura K, **Evans SR**. Group-sequential strategies for clinical trials when comparing two interventions using multiple co-primary endpoints. ICSA. 2015.
 61. Hujer AM, **Evans SR**, Jiang H, Hujer KM, Hall T, Marzan C, Jacobs MR, Sampath R, Ecker DJ, Domitrovic TN, Manca C, Chavda K, Zhang P, Chen L, Hill C, Perez F, Kreiswirth BN, Fowler V, Chambers HF, Bonomo RA. Informing antibiotic treatment decisions: evaluating rapid molecular diagnostics to predict susceptibility and resistance to *Escherichia coli* and *Klebsiella pneumoniae*. ECCMID. Copenhagen, Denmark. 2015.

62. Robertson K, Jiang H, **Evans SR**, Marra C, Berzins B, Hakim J, Sacktor N, Tullius Silva M, Campbell T, Walawander A, Schouten J. The International Neurological Study ACTG A5199 and A5271. CROI. Seattle, Washington. 2015.
63. Robertson K, Jiang J, **Evans SR**, Marra C, Berzins B, Hakim J, Sacktor N, Silva MT, Campbell T, Nair A, Schouten J. International neuropsychological normative study: neurocognitive comparison data in diverse resource-limited settings ACTG A5271. IAS. Vancouver, CA. 2015.
64. Wilkin T, Matining R, Sahasrabudde V, Godfrey C, Lungu T, Mwanahamuntu M, Bhosale R, **Evans SR**, Coombs RW, Firnhaber C. Factors associated with extensive cervical lesions among HIV-infected women screening for ACTG protocol A5282. CROI. Seattle, Washington. 2015.

Scholarly Presentations

Regional Presentations

1. **Evans SR**. Hosmer DW. Goodness of Fit in Two Models for Clustered Binary Data. Probability and Statistics Seminar, University of Massachusetts, Amherst, MA, 1998.
2. **Evans SR**. Hosmer DW. Goodness of Fit in Two Models for Clustered Binary Data. Department of Biostatistics and Epidemiology Doctoral Student Seminar, University of Massachusetts, Amherst, MA, 1998.
3. **Evans SR**. Equivalence Trials. Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2001.
4. **Evans SR**. Biostatistics in Medical and Public Health Research. Information Technology in Healthcare Working Group, Harvard Medical School, Boston, MA, 2003.
5. **Evans SR**. Statistical Careers in Clinical Trials, Bioterrorism, and Ecology. Statistics Career Night, BCASA, Boston, MA, 2003.
6. Zhang J, **Evans SR**. Informative Censoring: Practical Considerations. HIV Working Group, HSPH, Boston, MA, 2004.
7. **Evans SR**. Designs in Clinical Trials. Introduction to Statistics, Harvard Extension School, Cambridge, MA, 2004.
8. **Evans SR**. Biostatistics for High School Teachers. New Hampshire IMPACT Center, Plymouth State University, 2004.
9. **Evans SR**. What Do Biostatisticians Do? Mathematics Association at Plymouth State University, Co-Sponsored by the BCASA, Plymouth, NH, 2004.
10. Li L, **Evans SR**. A Comparison of Goodness-of-Fit Tests for the Logistic GEE Model. Longitudinal Data Working Group, HSPH, Boston, MA, 2004.
11. Yang Y, **Evans SR**. Recent Results in Neuro-AIDS Clinical Trials. Neuro-Statistics Working Group, HSPH, Boston, MA, 2004.
12. **Evans SR**. Exploring Mathematics Night: A Panel. Department of Mathematics and Statistics, University of New Hampshire, 2005.
13. **Evans SR**. Clinical Trials and Bioterrorism: Statistical Careers. Career Day, BCASA, Boston, MA, 2005.
14. **Evans SR**. Distance Education in Biostatistics: A Case Study. BCASA, Waltham, MA, 2006.
15. **Evans SR**. Why is Statistics Important? High School Statistics Day, BCASA, Newton, MA, 2006.
16. **Evans SR**. Futility Analyses and Predicted Intervals. CBAR, HSPH, Boston, MA, 2006.
17. **Evans SR**. Measuring LDL and Agreement. CBAR, HSPH, Boston, MA, 2006. **Evans SR**. Statistics and Biostatistics as a Career. Mathematics Career Day, Bentley College, Waltham, MA, 2007.

18. **Evans SR.** Data Monitoring in Clinical Trials Using Prediction. Children's Hospital, Boston, Harvard Medical School, MA, 2007.
19. **Evans SR.** Careers in Biostatistics and Biostatistical Design. Mathematics Seminar, Emmanuel College, 2007.
20. Yeh TM, **Evans SR.** A5252: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Combination Analgesic Therapy in HIV-Associated Painful Peripheral Neuropathy. Design Review, CBAR, Boston, MA, 2007.
21. Chen H, **Evans SR.** Assessment of HIV-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV Viral Load. Design Review, CBAR, Boston, MA, 2007.
22. **Evans SR, Ting N.** Careers in Clinical Trials and Biostatistics. Mathematics Career Day, University of Connecticut, 2008.
23. **Evans SR, Li L, Wei LJ.** Monitoring Clinical Trials Using Prediction. HIV Working Group, Department of Biostatistics, HSPH, Boston, MA, 2008.
24. **Evans SR.** Educating Young Students about Statistics and Study Design. Annual Meeting of the New Hampshire Teachers of Mathematics, 2008.
25. **Evans SR, Chen H, Yeh TM.** Neuropathy in the ALLRT Cohort. CBAR, HSPH, 2008.
26. **Evans SR.** Issues with Composite Endpoints. CBAR, HSPH, 2008.
27. Jiang H, **Evans SR.** A Randomized Clinical Trial of Chemotherapies for Kaposi 's sarcoma in HIV. Design Review, CBAR, Boston, MA, 2008.
28. Chen H, **Evans SR.** A Randomized Clinical Trial of Gentian Violet vs. Nystatin for the Treatment of Oral Candidiasis in HIV. Design Review, CBAR, Boston, MA, 2008.
29. **Evans SR.** Benefit:Risk in Clinical Trials. Midwest Biopharmaceutical Statistics Workshop (MBSW), 2009.
30. **Evans SR.** Noninferiority Clinical Trials. Massachusetts General Hospital Biostatistics Center Seminar, 2009.
31. **Evans SR.** Noninferiority Clinical Trials. CBAR, HSPH, 2009.
32. **Evans SR** and Wei LJ. Data Monitoring: Life beyond p-values. CBAR Staff Meeting, 2009.
33. **Evans SR.** Data Monitoring of Clinical Trials Using Prediction. Harvard Catalyst Biostatistics Program Seminar, The Harvard Clinical and Translational Science Center, 2010.
34. **Evans SR.** Biostatistics in Clinical Trials. Association of Teachers of Mathematics in New England (ATMNE), 2010.
35. **Evans SR.** Statistical Consulting in Lawsuits: Panel Discussion. BCASA, Boston, MA, 2010.
36. **Evans SR.** Adaptive Design. CBAR, HSPH, 2010.
37. **Evans SR** and Wei LJ. Noninferiority and ITT. CBAR Staff Meeting, 2010.
38. **Evans SR.** Noninferiority Clinical Trials. Principles and Practice of Clinical Research, Harvard Medical School, 2011.
39. **Evans SR.** Adapting Traditional Adaptive Designs: New Methods and Procedures. New Jersey Chapter of ASA, Annual Symposium on Adaptive Design, 2011.
40. **Evans SR.** Future HIV Clinical Trials: New Challenges. HIV Working Group, Department of Biostatistics, HSPH, 2011.
41. **Evans SR.** Academic Careers in Statistics. New England Statistics Symposium (NESS), 2011.
42. **Evans SR.** The Non-technical Side of Statistics: the Role of the Clinical Trial Statistician, CBAR, HSPH, 2011.
43. **Evans SR.** Benefit:risk Evaluation in Clinical Trials. CBAR, HSPH, 2011.
44. **Evans SR.** Noninferiority Clinical Trials. CBAR, HSPH, 2011.
45. **Evans SR.** Fundamentals of Clinical Trial Design. CBAR, HSPH, 2011.
46. Chen H, **Evans SR.** HPV and Oral Candidiasis. CBAR, HSPH, 2011.

47. Lee A, **Evans SR**. A Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Subclinical *Plasmodium falciparum* Parasitemia in HIV-infected Individuals. Design Review, CBAR, Boston, MA, 2011.
48. **Evans SR**. Diagnostic Trials: Design, Analyses, and Reporting. CBAR, HSPH, 2013.
49. **Evans SR**. Prediction for Interim Data Monitoring of Clinical Trials. HIV Working Group, Department of Biostatistics, HSPH, 2012.
50. **Evans SR**. Predicting the Future to Aid in Decision-Making in Medical Studies. Career Day, BCASA, Boston, MA, 2012.
51. **Evans SR**. Noninferiority Clinical Trials. Principles and Practice of Clinical Research, Harvard Medical School, 2012.
52. **Evans SR**. Exploring Mathematics Night: A Panel. Department of Mathematics and Statistics, University of New Hampshire, 2012.
53. **Evans SR**. What's the Question? CBAR, HSPH, 2012.
54. **Evans SR**. Benefit:risk Evaluation in Clinical Trials. CBAR, HSPH. 2012.
55. Lee A, **Evans SR**. Development of a Neuroimaging Network for the ACTG: Site Screening and Preparation a Limited Center Trial of the ACTG. Design Review, CBAR, Boston, MA, 2012.
56. **Evans SR**. Benefit:risk Evaluation in Clinical Trials. Tufts Clinical and Translational Science Institute, Tufts Medical Center, 2013.
57. **Evans SR**. Noninferiority Clinical Trials. Principles and Practice of Clinical Research, Harvard Medical School, 2013.
58. **Evans SR**. Response Adjusted for Duration of Antibiotic Risk (RADAR). University of Rochester. Department of Biostatistics and Bioinformatics Seminar. 2014.
59. **Evans SR**. DSMBs. City of Hope. CA. 2014.
60. **Evans SR**. Antibacterial Resistance and the ARLG. CBAR, HSPH, 2014.
61. **Evans SR**. Noninferiority Clinical Trials. Principles and Practice of Clinical Research, Harvard Medical School, 2014.
62. **Evans SR**. Clinical Trials, Pharmacogenomic Interplay in Biotransformation and Pharmacokinetics, University of Rhode Island. 2014.
63. **Evans SR**. Noninferiority Clinical Trials. Principles and Practice of Clinical Research, Harvard Medical School, 2015.
64. **Evans SR**. Using endpoint data to analyze patients rather than patient data to analyze the endpoints. University of Vermont. 2015.
65. **Evans SR**. Using endpoint data to analyze patients rather than patient data to analyze the endpoints. University of Massachusetts. 2015.
66. **Evans SR**. Clinical Trials and Diagnostics: Biostatistical Ideas. Rutgers University. 2015.
67. **Evans SR**. Careers in Clinical Trials. Boston University Career Night. 2015.
68. **Evans SR**. DOOR and RADAR. CBAR, HSPH, 2015.
69. **Evans SR**. Superbugs vs. Statistics. Massachusetts General Hospital Biostatistics Center Seminar, 2016.
70. **Evans SR**. Clinical Trials: Today and Tomorrow. CBAR, HSPH. 2016.
71. **Evans SR**. Using endpoint data to analyze patients rather than patient data to analyze the endpoints. Harvard Pilgrim Health Care. 2016.
72. **Evans SR**. Noninferiority Clinical Trials. Principles and Practice of Clinical Research, Harvard Medical School, 2016.
73. **Evans SR**. Using endpoints to analyze patients rather than patients to analyze the endpoints. CBAR, HSPH. 2016.
74. **Evans SR**. Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: Healthy Disruption for Clinical Trials and Diagnostic Studies. Beth Israel Deaconess Medical Center. 2017.

National Presentations

1. Ellis R, Robertson K, Yiannoutsos C, **Evans SR**, Bosch R. Association of HAART-Induced Virologic Suppression with the Prevalence and Incidence of HIV Neurocognitive Impairment and DSPN in the ALLRT Cohort. ACTG Meetings, Crystal City, VA, 2002.
2. Aberg J, Zackin R, **Evans SR**, Yang Y, Alston BL, Henry K, Glesby M, Brobst SW, Owens S, Fichtenbaum CJ. ACTG A5087: Comparing the Efficacy and Safety of Fenofibrate versus Pravastatin in HIV-Infected Subjects with Lipid Abnormalities. ACTG Meetings, Crystal City, VA, 2002.
3. Clifford DB, **Evans SR**, Yang Y, Acosta E, Gulick, RM. Impact of Efavirenz (EFV) on Neuropsychological Performance, Mood, and Sleep Behavior in HIV-Positive Individuals. ACTG Meetings, Washington, DC, 2003.
4. Robertson K, Ellis R, **Evans SR**, Yang Y. Clinical Validation of the ACTG Neuroscreen. ACTG Meetings, Washington, DC, 2003.
5. D'Amico R, **Evans SR**, Yang Y, Schnizlein-Bick C, Mildvan D. Pathogen-Specific Immune Responses in Opportunistic Infections. ACTG Meetings, Washington, DC, 2003.
6. **Evans SR**. Transition to Electronic or Web-based Newsletters. Council of Chapter Presentation, JSM, San Francisco, CA, 2003.
7. **Evans SR**. Assessment of the Agreement between the LDL Genzyme Assay and LDL Measured by Ultracentrifugation and the Applicability of the Friedewald Equation for Calculating LDL Measurements in ACTG A5087. ACTG Meeting, Baltimore, MD, 2005.
8. **Evans SR**. Phase II Trial of Prosaposin-derived Peptides for HIV-associated Sensory Neuropathies: First Use of Electronic Diary to Record HIV-Associated Neuropathic Pain. ACTG Meeting, Baltimore, MD, 2005.
9. **Evans SR**. The Value of Quantitative Measures in the Research Diagnosis of HIV-associated Neuropathy. ACTG Meeting, Baltimore, MD, 2005.
10. **Evans SR**, Mu Sigma Rho and ASA Chapters. Council of Chapters, JSM, Minneapolis, MN, 2005.
11. **Evans SR**, O'Neill R. Benefit:Risk Evaluation in Clinical Trials. Statistics Virtual Journal Club, Statistics Special Interest Area Community, Drug Information Association, 2008.
12. **Evans SR**, Li L, Wei LJ. Data Monitoring of Clinical Trials Using Prediction. ICSA, NJ, 2008.
13. **Evans SR**. Noninferiority Trials. ACTG Meetings, Washington DC, 2008.
14. **Evans SR**. Neuropathy in the ALLRT Cohort. ACTG Meetings, Washington DC, 2008.
15. **Evans SR**, Wei LJ. Data Monitoring of Clinical Trials Using Prediction. Statistics Virtual Journal Club, Statistics Special Interest Area Community, DIA, 2009.
16. **Evans SR**. Panelist. Interim Efficacy and Futility Analysis. FDA-Industry Workshop, 2009.
17. **Evans SR**. Statistical Careers in Biostatistics. Career Day, BCASA, Boston, MA, 2009.
18. **Evans SR**. Adaptive Designs. ACTG Group Meeting, 2010.
19. **Evans SR**. Challenges in Developing Tailored Therapies by Subgroup Identification. FDA/DIA Statistics Forum, 2010.
20. **Evans SR**. Personalized Medicine in Benefit:Risk Assessment. FDA-Industry Statistics Workshop, 2010.
21. **Evans SR**. Quantitative Benefit:Risk Evaluation with a Focus on Personalized Medicine. FDA Workshop: Using Quantitative Decision Analysis in the Regulation of Medical Devices, 2010.
22. **Evans SR**. The Statistical and Data Management Center. OHARA External Scientific Expert Group Meeting, NIH/NIDCR, 2011.
23. **Evans SR**. Benefit:risk Evaluation in Clinical Trials. CDER/FDA, 2011.

24. **Evans SR.** Panelist. Evolving Role of Data Monitoring Committees. FDA-Industry Statistics Workshop, 2011.
25. **Evans SR.** Design and Monitoring of Benefits and Risks in HIV Clinical Trials Using Prediction. ICSA, 2011.
26. **Evans SR.** Stopping Trials for Efficacy or Futility. ACTG Meeting, Washington DC, 2011.
27. **Evans SR.** On Design Issues in Clinical Trials. ACTG Meeting, Washington DC, 2011.
28. **Evans SR.** Peripheral Neuropathy in HIV. ACTG Meeting, Washington DC, 2011.
29. **Evans SR.** The Statistical and Data Management Center. ACTG Meeting, Washington DC, 2011.
30. Robertson K, Jiang J, Kumwenda J, Supparatpinyo K, **Evans SR**, Price R. A Multinational Study of Neurological Performance in Antiretroviral Therapy-Naïve HIV-1-Infected Persons in Diverse Resource-Constrained Settings. ACTG Meeting, Washington DC, 2011.
31. **Evans SR.** Benefit:risk Evaluation in Clinical Trials. The Center for Health Quality, Outcomes and Economic Research, United States Department of Veterans Affairs, 2012.
32. **Evans SR.** Benefit:risk Evaluation in Clinical Trials. NIAID/NIH. 2012.
33. **Evans SR.** What's the Question? ACTG Meeting, 2012.
34. **Evans SR.** Panelist. A Longitudinal Model and Graphic for Benefit-risk Analysis. Statistics Virtual Journal Club, Statistics Special Interest Area Community, DIA, 2012.
35. **Evans SR.** Panelist. New Approaches in the Evolution of the Independent Data Monitoring Committee (IDMC) in Clinical Trials. ICSA, 2012.
36. **Evans SR.** Discussant. Structured Benefit-Risk in the Current Regulatory Environment and the Implications for Clinical Statisticians. DIA. Boston MA. 2013
37. **Evans SR.** Statistical Considerations in the clinical trials evaluating Antibacterial Treatments. DIA. Boston MA. 2013.
38. **Evans SR.** Future Directions. SCT-FDA Benefit:Risk Workshop. Bethesda, MD. 2013.
39. **Evans SR.** Benefit-Risk Assessment in Clinical Development and Regulatory Review. DIA/FDA Statistics Forum. Bethesda, MD. 2013
40. **Evans SR.** Consider the "Order of Operations" in Benefit:Risk Evaluation. ICSA. Washington DC. 2013
41. **Evans SR.** Panelist. Help, I'm Supposed to Teach! How to Teach Biostatistics to Non-statisticians in Biomedical Environments. JSM. Montreal CA. 2013.
42. **Evans SR.** Response Adjusted for Duration of Antibiotic Risk (RADAR). Clinical Trial Transformation Initiative (CTTI) Statistical Issues Think Tank. 2014.
43. **Evans SR.** Response Adjusted for Duration of Antibiotic Risk (RADAR). FDA Statistical Association Benefit:Risk Symposium. 2014.
44. **Evans SR.** Discussant. FDA/NIH: The Development of New Antibacterial Products: Charting a Course for the Future. Bethesda, MD. 2014.
45. **Evans SR.** Using endpoint data to analyze patients rather than patient data to analyze the endpoints. JSM. Boston MA. 2014.
46. **Evans SR.** ASA: 175th Anniversary Celebration: The Future of Statistics in the Health Sciences, 2014.
47. **Evans SR.** Strength in numbers: Innovative Statistical Approaches that Clinicians Should Care About. ID WEEK. San Diego, CA. 2015.
48. **Evans SR.** Battling Superbugs with Statistical Thinking: Using Endpoints to Analyze Patients Rather than Patients to Analyze Endpoints. Mosteller Statistician of the Year Banquet. Boston Chapter of the ASA. Boston, MA. 2015.
49. **Evans SR.** Battling Superbugs with Statistical Thinking. Re-Entering Antibacterial Drug Development Summit, Boston, MA. 2015.

50. **Evans SR.** The Design of the Master Protocol for Multiple Investigational Diagnostics (MASTERMIND). SCT. Washington, DC. 2015.
51. **Evans SR.** Benefit:Risk Evaluation in Medicine: Discussant. JSM, Chicago, IL. 2016.
52. **Evans SR.** Advances in Design of Infectious Disease RCTs. Meet the Experts. ASM Microbe, Boston, MA, 2016.
53. **Evans SR, Huskins C.** DOOR and RADAR. Webinar. Centers for Disease Control and Prevention (CDC). 2016.
54. **Evans SR.** The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. NIAID. 2017.
55. **Evans SR.** Novel statistical designs in studies of antibiotic resistance. The NIAID Summer Retreat. 2017.
56. **Evans SR.** Challenges of the Clinical Use and Interpretation of Genotypic vs. Phenotypic Drug Resistance Testing. Food and Drug Administration. 2017.
57. **Evans SR.** Using outcomes to analyze patients rather than patients to analyze outcomes. World Antimicrobial Congress. Washington DC. 2017.
58. **Evans SR.** Benefit-Risk Evaluation for Diagnostics: A Framework (BED-FRAME). ENAR. Washington, DC. 2017.
59. **Evans SR.** Improving the efficiency of medical device clinical trials by combining simulations and experiments (Discussant). JSM, Baltimore, MD. 2017.
60. **Evans SR.** DMCs and Benefit:Risk. JSM, Baltimore, MD. 2017.
61. **Evans SR.** Meet the Professor. ARLG: New Methodologies. IDWEEK. San Diego, CA USA. 2017.
62. **Evans SR, Liu Y.** Healthy Disruption for Diagnostic Studies through Pragmatic Benefit-Risk Evaluation: Average Weighted Accuracy (AWA) Webinar sponsored by the Medical Devices and Diagnostics (MDD) Section of the ASA. 2017.
63. **Evans SR.** Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. 2017.
64. **Evans SR.** Panelist. Incorporating Real World Evidence in Clinical Trials. Clinical Trials Transformation Initiative. Washington, DC. 2018.
65. **Evans SR.** Panelist. Decision Analysis, Risk Stratification of Diagnostic Test Performance. ASA / AdvaMed Medical Device Statistical Issues Conference. Washington, DC. 2018.
66. **Evans SR.** Panelist. Utility of Quantitative Benefit-risk Assessment for Regulatory Decision-making. ASA Biopharmaceutical Regulatory Industry Statistics Workshop. Washington, DC. 2018.
67. **Evans SR.** Healthy Disruption for Clinical Trials. JSM. 2018.
68. Liu Y, **Evans SR.** Healthy Disruption for Diagnostic Studies through Pragmatic Benefit:risk Evaluation. JSM. 2018.
69. **Evans SR.** Pragmatic Benefit:risk Assessment in Clinical Trials. Webinar for the Biopharmaceutical Section of the ASA. 2018.
70. **Evans SR.** Pragmatic Benefit:risk Assessment in Clinical Trials: A New Paradigm Using Pairwise Comparison of Patients. Society for Clinical Trials. 2018.
71. **Evans SR.** Meet the Professor. ARLG: Making the impossible, possible: Pragmatic clinical trials. IDWEEK. San Fransisco, CA USA. 2018.

International Presentations

1. **Evans SR.** Statistical Issues and Design. Assessment of NeuroAIDS in Africa, Arusha, Tanzania, Africa, 2006.
2. **Evans SR.** Benefit:Risk Assessment in Clinical Trials. Keynote Address. Japanese Biometric Society, Kyoto, Japan, 2009.

3. Hamasaki T, **Evans SR**. Professional Training and Education of Statisticians in Drug Development. The 8th Biostatistics Forum, Kyushu University School of Medicine, 2009.
4. **Evans SR**. Data Monitoring of Clinical Trials Using Prediction. Japanese National Institute of Public Health, Tokyo, Japan, 2009.
5. **Evans SR**. Noninferiority Clinical Trials. Interfarma and ANVISAs' Multidisciplinary Symposium on Noninferiority Trials in Brazil. Keynote Address. Brasilia, Brazil, 2010.
6. **Evans SR**. Panelist. International Collaborations and Networking of the Biometricians to Develop Statistical Methodologies and to Solve Global Statistical Issues. International Biometrics Conference, Kobe, Japan, 2012.
7. **Evans SR**. Using endpoint data to analyze patients rather than patient data to analyze the endpoints. PMDA, Tokyo, Japan. 2015.
8. **Evans SR**. Optimizing Clinical Trials Using Novel Designs. SCT. Liverpool, England. 2017.
9. Miyahara S, Montepiedra G, Kim S, **Evans SR**, Gupta A, Swindells S, Chaisson RE, Ramchandani R. Risk-benefit analysis using novel methods in the A5279 latent-TB clinical trial. 49th Union World Conference on Lung Health. The Netherlands, 2018.

Other Presentations

Chair at Professional Meetings

1. JSM: Ecological Statistics, 2002.
2. IMS Meeting: Statistics and Sports, 2003.
3. JSM: Statistics in Sports, Comparing Performance: Ranking and Rating, 2003.
4. JSM: Distance Learning - Teaching Statistics in the Health Sciences, 2005.
5. JSM: Distance Education in Biostatistics (Roundtable Luncheon), 2005.
6. SCT: Benefit-Risk Evaluation in Clinical Trials (Plenary), 2006.
7. BCASA: Statisticians and FDA Advisory Committees, 2007.
8. JSM: Luncheon, Section on Statistics in Sports, 2008.
9. Graybill Conference: The Future of the Education of Clinical Trial Statisticians, 2008.
10. Harvard- Schering-Plough Workshop: Benefits and Risks, 2008.
11. ENAR: Statisticians and FDA Advisory Committees, 2008.
12. ENAR: Education of Clinical Trial Statisticians: Changing with the Times, 2008.
13. JSM: Luncheon, Section on Statistics in Sports, 2009.
14. HSPH-Merck Workshop: Efficacy and Safety of Vaccines, 2010.
15. FDA-Industry Statistics Workshop (Session Organizer: Benefit:Risk Evaluation), 2010.
16. ICSA: Biosimilars, 2012.
17. ICSA: Issues in Infectious Disease Clinical Trials, 2012.
18. ICSA: Innovations in the Statistics Classroom, 2012.
19. SCT: DSMBs, 2013.
20. ASA: 175th Anniversary Celebration: Statistics in Sports, 2014.
21. SCT: Superbugs, 2015.
22. JSM: Superbugs, 2015.
23. SCT: Trial of the Year, 2016.
24. SCT: Pragmatic Trials, 2016.
25. BCASA: The Future of Clinical Trials, 2016.
26. World Antimicrobial Congress: Noninferiority Trials. 2016.
27. ASA Webinar on Careers in Sports Analytics. 2016.
28. JSM: Complex Clinical Trials. 2017.
29. SCT: Trial of the Year, 2017.

30. SCT: Trial of the Year, 2018.
31. CTTI: Incorporating Real World Evidence in Clinical Trials, 2018.
32. ASA Webinar on Careers in Sports Analytics. 2018.

Corporations

1. **Evans SR.** Equivalence Trials: All Trials are Not Created Equal. Pharmaceutical Product Development, Wilmington, NC, 2001.
2. **Evans SR.** Wei LJ, More Informative Monitoring of Clinical Trials Using Prediction. Schering-Plough, NJ, 2008.
3. **Evans SR.** Wei LJ, Interim Monitoring of Clinical Trials Using Prediction. Merck, 2008.
4. **Evans SR.** Special Topics in Clinical Trials. Sunovion, MA, 2010.
5. **Evans SR.** Special Topics in Clinical Trials. Alcon, TX, 2010.
6. **Evans SR.** Special Topics in Clinical Trials. Boehringer-Ingelheim, CT, 2011.
7. **Evans SR.** Benefit:risk Evaluation. Alcon, TX, 2012.
8. **Evans SR.** Benefit:risk Evaluation in Clinical Trials. Boehringer-Ingelheim, CT, 2013.
9. **Evans SR.** Benefit:risk Evaluation in Clinical Trials. Merck, 2013.
10. **Evans SR.** Using Endpoints to Analyze Patients Rather than Patients to Analyze Endpoints. Webinar. GSK. 2016.
11. **Evans SR.** Using Endpoints to Analyze Patients Rather than Patients to Analyze Endpoints. Webinar. Vir. 2017.
12. **Evans SR.** Predicted Intervals. Webinar. Vir. 2017.

High Schools

1. **Evans SR,** Evans RC. Mathematics and Statistics Activities. Navajo GED Program, Navajo Nation, AZ, 2004.
2. **Evans SR.** Biostatistics and Clinical Trials. Silver Lake Regional High School, Kingstown, MA, 2005.
3. **Evans SR.** Statistics, Biostatistics, and Clinical Trials. Silver Lake Regional High School, Kingstown, MA, 2006.
4. **Evans SR.** Statistics, Biostatistics, and Clinical Trials. Milton High School, Milton, MA, 2006.
5. **Evans SR.** The Interesting Uses of Biostatistics. The British School of Boston, 2007.
6. **Evans SR.** Biostatistics. O'Bryant School of Math and Science, 2010.
7. **Evans SR.** Superbugs and Clinical Trials. Acton-Boxborough High School, 2015.

University Service (Harvard University)

2018	Biostatistics and Bioinformatics Working Group
2018	Biostatistics Department Chair Search Committee
2006-2009	Human Subjects Committee, Institutional Review Board (IRB), HSPH
2006	Frederick Mosteller Memorial Committee, Harvard University

Professional Society Membership and Leadership

Society for Clinical Trials

2018-2019	Planning Committee
2015-2018	Chair (2016-2018), Trial of the Year Committee
2014-2018	Board of Directors
2014-2015	Chair, Development Committee

American Statistical Association (ASA)

2018-2020 Board of Directors
2014-2016 Mentorship Program Mentor

Section on Teaching Statistics in the Health Sciences (TSHS)

2014 Fellows Committee
2007, 2009 Distinguished Achievement Award Committee (Chair, 2009)
2007-2009 Young Investigator Award Committee (Chair, 2009)
2008 Chair, TSHS Section
2008 Chair, Executive Committee
2007-2008 Chair, Nominations Committee

Section on Medical Devices and Diagnostics (MDD)

2016 Program Chair

Section on Statistics in Sports

2008 Chair, Nominations Committee
2007 Chair, Executive Committee
2007 Chair, SIS Section
2007 Judge, JSM Poster Competition

Boston Chapter

2011, 2014 Chair, Chapter Service Award Committee
2003-2006 President
2007-2010 Past President
2001-2002 Program Chair
2000-2018 Planning Committee

Mu Sigma Rho, the National Honorary Society for Statistics

2009 Constitution Review Committee
2007-2013 Board of Directors; Secretary-Treasurer (2007-2010)
2004-2010 Founding Sub-Committee Member, Affiliate Chapter (BCASA)

Conference Program Committees

2017 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
2016 Joint Statistical Meetings
2016 Antibiotic Workshop: Society for Healthcare Epidemiology of America
2015 Program Chair / Executive Committee, ICSA
2014 Program Chair / New England Statistics Symposium (NESS)
2014 175th Celebration of ASA Committee
2012 ICSA
2009 FDA-Industry Statistics Workshop
2008 ENAR
2008 Graybill Conference (Biopharmaceutical Statistics)
2008, 2010 Harvard-Schering-Plough Workshop
2007-present Co-Chair, New England Symposium on Statistics in Sports (NESSIS)
2006 Society for Clinical Trials
2004 International Conference on the Analysis of Genomic Data

Professional Memberships

American Statistical Association (ASA), Society for Clinical Trials (SCT), Infectious Disease Society of America (IDSA), International Biometric Society Eastern North American Region (ENAR), Drug Information Association (DIA), International Society for Clinical Biostatistics

(ISCB), American Society for Microbiology, American Association for the Advancement of Science (AAAS)

Editorial Peer Review Activities

Editor-in-Chief

2016-present *Statistical Communications in Infectious Diseases* (SCID)

2014-present *CHANCE*

Special Section Co-Editor

2018-present Innovations in Design, Education, and Analysis (IDEA), *Clinical Infectious Diseases*

Associate Editorships

CHANCE; Drug Information Journal; Public Library of Science (PLoS) Clinical Trials; Malawi Journal of Applied Sciences and Innovation; Case Studies in Business, Industry, and Government Statistics; PLoS ONE

Journal Reviewer

New England Journal of Medicine; Nature Medicine; Statistics in Medicine; Clinical Trials; The American Statistician; Journal of Biopharmaceutical Statistics; Computational Statistics and Data Analysis; Journal of Statistics Education; CHANCE; Statistical Education Research Journal; Medical and Pediatric Oncology; Pediatric Blood and Cancer; Statistics in Sports Anthology; NeuroImage; Journal of Quantitative Analysis in Sports; PLoS ONE; Case Studies in Business, Industry, and Government Statistics; Annals of Neurology; Future Virology; European Academy of Dermatology and Venereology; Antimicrobial Agents and Chemotherapy; HIV Clinical Trials; Circulation

Grant Reviews

- NIAID/NIH: Fecal Microbiota Transplant for *C. difficile* Infection in Solid Organ Transplant Recipients
- NIAID/NIH: Clinical Trial Grant Applications
- NIAID/NIH: Clinical Trial Planning Grant Program and Clinical Trial Implementation
- NIDCD/NIH: Clinical Trials in Communication Disorders
- NIA/NIH: New Interventions for Menopausal Symptoms
- NIMH/NIH: HIV and Psychiatric Comorbidity Research Project
- NHLBI/NIH: Cord Blood Transplantation
- NHLBI/NIH: SCCOR in Transfusion Biology and Medicine
- NHLBI/NIH: HAART: Cardiovascular Toxicities, Special Emphasis Panel

Other Reviews

- Tenure Review, Duke University
- Distinction Committee, Boston University

External Activities / Partnerships

Visiting Professor

2010-2016 Department of Biostatistics and the Center for Advanced Medical Engineering

and Informatics, Osaka University, Japan

Secondary Appointments

2016-present Faculty, Sports Analytics Laboratory, Department of Statistics, Harvard University

Clinical Trials Transformation Initiative (CTTI)

2016-present Steering Committee
2016-present Team Leader, Real World Evidence project

American Statistical Association (ASA)

2018-2020 Founders Award Committee
2018-present Caucus for Academic Representatives
2014-present Committee on Publications
2013-2015 Archives and Historical Materials Committee
2006-2011 Chair (2009-2011), Development Committee
2009-2010 Public Awareness Working Group
2009 Representative, Congressional Visit
2002-2004 Committee on Statisticians in Defense and National Security

Mock FDA Advisory Committee and Other Advisory Activities with Industry

Cardinal Health (2018), Spark (2017), Braeburn (2017), Lipocine (2017), Stryker (2017), Claret Medical (2017), Vir (2017), Arrebus (2017), Dexcom (2016), Shionogi (2016), Zeiss (2016), Amgen (2015), AstraZeneca (2015), Teva (2015), Repros (2015), Mannkind (2014), QRx Pharma (2014), Merck (2013), Chelsea (2013), FzioMed (2013), Cubist (2013), Alcon (2012), Affymax (2011, 2012), CIS Biotech (2009), Intermune (2009, 2010), Genentech (2007-2010), BMS (2006).

Scientific Advisory Boards, Think Tanks, and Expert Panels

2018 Margolis Center for Health Policy: Understanding the Development Challenges Associated with Emerging Non-traditional Antibiotics
2018-present Executive Committee: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, and Networks (ACTION)
2018 Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT): Research Design Recommendations for Clinical Trials of Opioid Sparing in Patients with Acute and Chronic Pain
2018 FDA Public Workshop: Development of Nontraditional Therapies for Antibiotic Infections
2017 Consortium on Clinical Endpoints and Procedures for Peripheral Neuropathy Trials (CONCEPT)
2016-present QSPI: Chair of DMC Benefit:risk Working Group
2016-present Executive Committee: THALES Trial (AstraZeneca)
2015-present Executive Committee: SOCRATES Trial (AstraZeneca)
2015 Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)
2014 Brookings Institute: Oral Antibacterial Drug Development
2014 CTTI: Statistical Issues Think Tank
2013-present Quantitative Sciences in the Pharmaceutical Industry (QSPI): Benefit:Risk Working Group
2013 Preclinical Pain Research Consortium for Investigating Safety and Efficacy (PPRECISE)

2012-2013	Muscle Study Group
2011-2013	Johns Hopkins University: Novel Therapeutics in HIV Cognitive Disorders
2011	Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)
2011	HIV/AIDS Network Coordination (HANC): Behavioral Sciences Working Group
2007-2012	UCSD: HIV Neurobehavioral Research Center (HNRC)

Data Safety and Monitoring Boards (DSMBs)

NIH

- Chair, Adolescent Trials Network (ATN), NICHD
- Chair, Microbial restoration in Clostridium difficile Associated Disease (CDAD), NIAID
- Directed Antimicrobial Therapy for CA-Pneumonia, NIAID
- Malaria Prevention in Pregnancy, NIAID
- Duchenne Muscular Dystrophy Trial, NINDS
- Antibiotics for MRSA, NIAID

Industry

- Chair, ABP 710 for Rheumatoid Arthritis, Amgen
- Chair, GS-9876 for Cutaneous Lupus Erythematosus, Gilead
- TAPPAS Trial for Advanced Angiosarcoma, Tracoon
- Deutetrabenazine for Tourette Syndrome in Children, Nuvelution
- ProstAtak for Prostate Cancer, Advantagene
- Plazomicin for CRE, Achaogen
- Biosimilar for Breast Cancer, Pfizer
- Clofazimine for MDR TB
- Major Depressive Disorder, Roche/Genentech
- Muscle loss, Novartis
- Biologic in Renal Transplant, Novartis
- Bladder Pain, Taris Biomedical
- LABA Trial for Asthma, Novartis
- QVM-149 for Asthma, Novartis
- CRZ533 in myasthenia gravis, Novartis
- Alisertib for Relapsed/Refractory Peripheral T-Cell Lymphoma, Millennium
- Chair, Varenicline tartrate for smoking cessation, Pfizer
- Chantel for smoking cessation, Pfizer
- Orteronel for Prostate Cancer, Millennium
- Voriconazole for Invasive Candidiasis and Candidemia, Pfizer
- BioFoam Surgical Matrix in Liver Surgery, CryoLife/Averion
- Lersivirine for HIV, Pfizer
- PF-02545920 for Schizophrenia, Pfizer
- CP-601,927 for Major Depression, Pfizer
- Ocrelizumab for RRMS, Genentech/Roche
- Ocrelizumab for PPMS, Roche
- Cardiac Device, AAI International
- Cardiac Device, Medical and Technical Research Associates (MTRA)
- Deutetrabenazine for Moderate to Severe Tardive Dyskinesia, Teva
- Tourette's syndrome, PRA Health Sciences
- Clofazimine for MDR tuberculosis, Novartis
- CDZ173 in autoimmune disease, Novartis

- Advanced solid tumors, Five Prime
- Atypical hemolytic uremic syndrome (aHUS), Alexion
- Avelumab for ovarian cancer, Syndax
- Hemophilia, Shire
- Huntington's disease, WAVE
- Alzheimer's disease, Roche/Genetech

Academic Hospital / Other

- PALbociclib CoLLaborative Adjuvant Study (PALLAS), Breast International Group
- Chair, MedCHEC, Boston University
- FIRSTHD, Huntington's Study Group
- REACH2HD, Huntington's Study Group
- Endoscopic resection of large colorectal polyps, Dartmouth College
- Citalopram in First Episode Schizophrenia, Massachusetts General Hospital
- PARAFU, Johns Hopkins University
- Patent Foramen Ovale for closer of heart hole in Stroke and TIA, HCRI
- Folate with B12 for Schizophrenia, Massachusetts General Hospital
- International Studies, HIV Neurobehavioral Research Center (HNRC)
- Ziprasidone for Schizophrenia, Massachusetts General Hospital

Teaching / Learning Portfolio

Courses Taught (at HPSH)

Primary Faculty

- Principles of Clinical Trials (BST 214 at HSPH; taught for 12 semesters)
- Advanced Topics in Clinical Trials (BST 238 at HPSH: taught for 2 semesters)
- STAT E-102: Introduction to Biostatistics (STAT E-102 at Harvard University; taught for 12 semesters; traditional and distance learning)

Secondary Faculty

- Statistical and Quantitative Methods for Pharmaceutical Regulatory Science (BST 523 at HSPH; taught for 3 semesters)

Guest Lecturer

- Advanced Topics in Clinical Trials (BST 238 at HPSH). Futility and Predicted Interval Plots) 2013.
- Design and Monitoring of Adaptive Clinical Trials (BST 276 at HSPH). DSMBs and Predicted Interval Plots (PIPs). 2014.
- Design and Monitoring of Adaptive Clinical Trials (BST 276 at HSPH). DSMBs and Predicted Interval Plots (PIPs). 2016.

Short Courses Taught at Professional Meetings and Other Venues

2018	Principles for New Clinical Trialists; Deming Conference on Applied Statistics
2017	ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop: Futility Analyses in Confirmatory Clinical Trials - Methods and Procedures
2017	Deming Conference on Applied Statistics: Hot Topics in Clinical Trials
2016	Osaka University Medical School: Thinking Clinical Trials
2016	Harvard Catalyst The Harvard Clinical & Translational Science Center: A Comprehensive Tour of Modern Clinical Trials with Software
2015	FDA (CDRH): Biostatistics Lecture Series
2015	Osaka University Medical School: Thinking Clinical Trials

2015 National Cerebral and Cardiovascular Center of Japan: Clinical Trials
2013 DIA/FDA Statistics Forum: Benefit:risk Evaluation
2013 Biopharmaceutical Section of ASA (webinar): DSMBs
2013 GSK: Benefit:Risk Evaluation
2012 Osaka University Medical School: thinking Clinical Trials
2012 National Cerebral and Cardiovascular Center of Japan: Clinical Trials
2011 FDA (CDRH): Benefit:risk Evaluation in Clinical Trials
2010 FDA-Industry Workshop: Hot Topics in Clinical Trials
2010 Statistical Society of Australia / Australian Statistical Conference: Topics in Clinical Trials
2010 Deming Conference on Applied Statistics: Benefit:Risk Assessment, Subgroup Analyses, and Prediction for Interim Data Monitoring
2009 FDA-Industry Workshop: Benefit:Risk Assessment
2009 Biopharmaceutical Applied Statistics Symposium (BASS): Fundamentals for Clinical Trial Statisticians
2009 Society for Clinical Trials: Hot Topics in Clinical Trials
2009 Osaka University Medical School: Thinking Clinical Trials
2009 Harvard Medical School and the University of Sao Paulo: Clinical Trials for Scholars in Clinical Research
2009 Pharmaceutical Education Research Associates: Basic Clinical Statistics for Non-Statisticians
2009 University of Colorado: Noninferiority Trials
2008 Joint Statistical Meetings: Hot Topics in Clinical Trials
2008 Graybill Conference: Hot Topics in Clinical Trials
2008 Society for Clinical Trials: DSMBs
2008 Beth Israel Deaconess Medical Center, Grand Rounds Series: Statistical Tutorials for Clinicians
2008 Pfizer: Training for Clinical Trial Statisticians
2008-2011 American Neurological Association: Summer Course for Clinical and Translational Investigators in Neurology and Neuroscience
2007 BASS: Hot Topics in Clinical Trials
2007 FDA-Industry Workshop: DMCs
2001-2009 Pharmaceutical Education Research Institute (PERI): Basic Training Course for New Clinical Statisticians
2005 PERI: STATS 101: Introduction to Statistical Thinking in Drug Development

Doctoral Oral Exam Committee

2017-2018 Derek MacFadden, Infectious Disease Epidemiology, HSPH

Other Mentoring

2017-present Mentor in DMID/NIAID/NIH DSMB Mentorship Pilot Program

Public Health Practice Portfolio

Participation on Advisory Panels

2001-present Special Government Employee (SGE), Food and Drug Administration (FDA) Division of Anti- Infective Drug Products, Center for Drug Evaluation and Research (CDER) 2001-2005; Medical Devices Advisory Committee, Center for Devices and Radiological Health (CDRH) (2005-present)

Testimony
2004-2006

Expert Witness, Commonwealth of Massachusetts